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Objectives/Research Questions: The purpose of this study was to assess existing 
curricula regarding HIV positive pregnant women in genetic counseling graduate programs.  
Methods:  Genetic counseling programs were surveyed to assess existing curricula 
regarding prevention and treatment issues for HIV positive pregnant women.  Programs were 
asked to identify their need for HIV-related educational materials, specifically issues and content 
needed to provide effective education for students and types of materials that would most benefit 
programs.   
Results:  Of the 32 graduate genetic counseling programs, 26 (81.3%)  responded to the 
survey.  The data show that 65.4% currently offer HIV education in their curriculum.   With 
regard to development of educational materials to address HIV in pregnancy, 64.3% (9/14) of 
programs that provide HIV education and 88.9% (8/9) of programs that provide no HIV 
education indicated they would benefit from development of these materials. The most 
commonly requested materials were webinars, PowerPoint presentations, and clinical case 
examples. 
Conclusions:  The results of this study indicate a need for the development of additional 
educational materials addressing issues specific to HIV positive pregnant women and reduction 
of perinatal transmission.   Through the Pennsylvania/MidAtlantic AIDS Education and Training 
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University of Pittsburgh, 2011 
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Center, web-based seminars and other educational materials were developed for distribution to 
genetic counseling programs. 
Implications for Public Health:  HIV is a major public health issue for all health-care 
providers who work with women of child-bearing age.  Improving knowledge of HIV prevention 
and treatment in pregnant women is important for genetic counselors who may encounter HIV-
positive pregnant women in their clinical practice.    
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1.0  INTRODUCTION 
1.1 DESCRIPTION OF THE PROBLEM AND SPECIFIC AIMS 
HIV has been described as the most significant public health problem of our time1.  In 1984 
when the epidemic began, HIV/AIDS was primarily characterized as a disease of homosexual 
males.  Since then, however, the numbers of women being diagnosed with AIDS has increased 
from 8% of all cases in 1985 to 26% in 20082, 3.  In 2009, the Centers for Disease Control and 
Prevention (CDC) reported that nearly a quarter of the people living in the United States who 
have HIV were women2, 3.  The number of affected women is reported as being approximately 
280,000 with 80% of these women becoming infected due to high risk heterosexual contact3.   
For women of all races and ethnicities, the rates of new diagnoses were highest between the ages 
of 15 and 393.  This indicates that the majority of women becoming infected with HIV are of 
reproductive age.   
Due to advances in management and treatment for HIV, individuals with HIV have been 
living longer4-8.  A study conducted by Emory University indicated that the average lifespan of a 
person following diagnosis with HIV has jumped from 7 years in 1993 t o 24 years in 20066. 
Because of this, an HIV diagnosis is now largely becoming a chronic disease which requires 
lifelong management.  More women with HIV are having children due to increased life 
expectancy and increased quality of life.  The CDC estimates that approximately 6000 to 7000 
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women living with HIV will choose to become pregnant each year.9   Perinatal transmission of 
HIV is the leading cause of HIV in children in the United States.   N early all children infected 
with HIV in the United States have become infected following exposure during pregnancy, 
childbirth, or breastfeeding2, 3, 9, 10.  In 1994, s tudies first found that antiretroviral medications 
taken during pregnancy reduced the risk of perinatal transmission.  S ince then, the rates of 
perinatal transmission have decreased dramatically and only 73 c hildren were diagnosed with 
HIV in 200710.  Today, the majority of perinatal transmission is due to mothers not knowing that 
they were HIV-positive during the pregnancy.  It is estimated that if left untreated, HIV-positive 
pregnant women will have a 30-45% chance of infecting their child with the virus.  If infected 
mothers take one antiretroviral during pregnancy, the risk of transmission drops to 8%, and if 
three antiretroviral drugs are taken, the risk declines to lower than 2%9, 11.  These findings have 
prompted the CDC to recommend that all pregnant women be given an HIV test during the first 
trimester and again prior to labor and delivery12.   In addition to screening of pregnant women, 
ten states have initiated HIV testing of newborns as part of their newborn screening programs.  
The majority of states only perform newborn testing if the HIV status of the mother is unknown 
or is not clear.  The only state to include HIV on their standard newborn screen is New York.13 
Because of the increasing numbers of HIV-positive women who are living longer and 
deciding to have families as well as the decision of states to initiate HIV testing of newborns, the 
needs of HIV-positive women may become relevant in the field of genetic counseling.  
According to the 2006 de finition of genetic counseling released by the National Society of 
Genetic Counselors (NSGC), genetic counseling is “the process of helping people understand 
and adapt to the medical, psychological and familial implications of genetic contributions to 
disease. This process integrates interpretation of family and medical histories to assess the 
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chance of disease occurrence or recurrence, education about inheritance, testing, management, 
prevention, resources, and research, and counseling to promote informed decisions and 
adaptation to the risk or condition”14.  HIV is not a genetic condition that would be the object of 
focus during a counseling session; however women with HIV have unique psychosocial needs 
and medical issues that should be taken into consideration during a counseling session15-17.  HIV 
is part of a woman’s medical history, and this diagnosis can have implications for treatment, 
management, and recommendations during pregnancy11.  Women with HIV are not just women 
with HIV, they are women who are being referred for counseling due to advanced maternal age, 
genetic risk, medication exposure, or any other reason that a woman without HIV would be 
referred for genetic counseling. 
In order to investigate the role of genetic counseling in the care of HIV-positive pregnant 
women, I propose to assess the current educational content addressing HIV utilized by genetic 
counseling programs in the United States and Canada.  Using this information, I will develop 
educational materials for genetic counseling programs to facilitate the incorporation of the 
special needs of an HIV-positive woman receiving prenatal counseling into their existing 
curricula.  
1.1.1 Specific Aim 1 
Survey current genetic counseling programs in the United States and Canada and determine what 
current HIV content exists in higher education programs for genetic counseling students.  
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1.1.2 Specific Aim 2 
Survey current genetic counseling programs in the United States and Canada and identify types 
of educational materials that would be useful to genetic counseling program directors in 
providing education to their students.   
1.1.3 Specific Aim 3 
Analyze data collected from Aims 1 a nd 2 and develop educational product for genetic 
counseling programs to address the needs of HIV-positive pregnant women. 
1.2 HUMAN IMMUNODEFICIENCY VIRUS 
1.2.1 Disease Basics 
In the early 1980’s, homosexual men in San Francisco starting presenting with a condition 
characterized by opportunistic infections resulting from a severely compromised immune system 
18.  The condition that affected these men would eventually be referred to as acquired immune 
deficiency syndrome (AIDS).  At the time of the initial outbreak, the cause of AIDS was 
unknown, and it was diagnosed almost primarily in men who were having sex with men (MSM).  
In 1983, a virus was isolated from affected individuals and found to be the responsible for 
AIDS19.  T he newly discovered virus was named human immunodeficiency virus (HIV)19  
Following initial HIV infection, the virus infects the cells of the body’s immune system, 
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specifically macrophages and CD4+ T-cells.  These cells are integral in the recognition of 
foreign pathogens, initiation of immune responses, and prevention of infection20.  As  HIV 
infection progresses, the number of circulating CD4+ cells is  depleted, which eventually leads to 
AIDS. 
HIV is spread by three primary routes:  sexual, parenteral (blood borne), and perinatal.20  
Sexual transmission of the HIV virus can occur following unprotected male to male, male to 
female, female to male, or female to female sexual contact20.  The risks of infection are the 
highest following unprotected anal and vaginal intercourse, although there is a risk of infection 
following unprotected oral sex19, 20.  Some of the sexual risk factors that put an individual at risk 
for becoming infected with HIV are having multiple sex partners and being infected with other 
sexually transmitted infections (STIs).   
Perenteral (blood borne) infection is characterized by infection following contact with 
contaminated blood products.  T his can occur following a blood transfusion or occupational 
exposure to HIV-positive blood or intravenous drug use with contaminated needles20.   Infection 
following intravenous or injection drug use can be caused by exposure to HIV-positive blood 
from syringes, rinse water, or other equipment that is used in the preparation of injection drugs.19   
The third most common route of HIV infection is perinatal infection – the passing of HIV 
from a mother to child during pregnancy, labor and delivery, or breast feeding19, 20.  I t is 
estimated that 91% of pediatric HIV cases in the United States are due to perinatal 
transmission20.  P erinatal transmission risks will be discussed in more detail later in this 
introduction. 
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1.2.2 HIV Viral Life Cycle 
HIV is classified as a lentivirus belonging to the retrovirus family.  T he lifecycle of HIV is 
complicated and is reliant upon both viral and host cell proteins18.  HIV targets cells that have 
CD4+ receptors on their surface, namely macrophages and CD4+ T-cells.  B y using two 
additional co-receptors, HIV is able to differentiate between these two cell types.  H IV is an 
enveloped virus that has two glycoproteins on i ts surface, gp41 and gp120, which aid in the 
initial binding and entry into host cells.  Once the virus enters a cell, the envelope is dissolved 
and the viral RNA is released into the cytoplasm.18 
In the cytoplasm, reverse transcriptase transcribes the RNA into DNA, which is then 
integrated into the host cell’s cellular DNA.  This ensures that each time the host cell replicates, 
a copy of the HIV DNA will also be copied.   Integration of the HIV genome into host cells also 
allows the HIV virus to use the host cell’s machinery for transcription and translation, which 
results in the production of new virus particles. The RNA transcript serves not only as a template 
for protein production but also as the genome for newly forming virus particles.   The lifecycle of 
HIV is complete once a new virus buds from the surface of the host cell, taking part of the host 
cell’s membrane along with it.18  A summary of the HIV lifecycle can be seen in Figure 1. 
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Figure 1:  Schematic of the HIV Lifecycle18      
Copyright Permissions Received                                                                                             
1.2.3 Natural History of HIV Infection 
Untreated HIV is a chronic illness that progresses through stages based on the clinical 
manifestations of the disease and CD4+ T-cell counts20.  Clinical conditions associated with HIV 
tend to cluster around CD4+ T-cell counts, with more severe infections manifesting as CD4+ T-
cell counts drop.  Staging of HIV infection is important for clinicians to make treatment and 
management decisions for the patient20.   
Five to thirty days following exposure to HIV, some individuals may develop flu-like 
symptoms, but others will have no s igns of illness. This stage is called the infection stage and 
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during this stage, the HIV virus begins to replicate at high rates (as many as several million 
copies of HIV RNA per mm3 of plasma) and integrate itself into CD4+ cells. 20, 21  
During the next stage of HIV infection, the response stage, the body’s immune system 
recognizes and combats the virus. The virus load is decreased in the plasma, and by this point the 
virus is already integrated into CD4+ cells and can remain latent or can produce new virus 
particles. This is the point where an individual becomes positive for HIV antibodies, meaning 
they have antibodies against the HIV virus19. The HIV-infected cells continue to replicate and 
divide, increasing the number of latent HIV viruses20.  Within the plasma, the amount of viruses 
reaches an equilibrium between those that are produced from infected cells and those that are 
cleared by the immune system.  This equilibrium is referred to as the “viral set point”20.  The 
amount of virus present in the “viral set point” varies by individual, and is highly predictive of 
the rate of disease progression in HIV20. 
A relatively stable stage follows the response stage, and during this time period an 
individual infected with HIV may not experience any symptoms or know that they are infected. 
Symptoms of HIV can take several years to develop, and are triggered by the body’s CD4+ T-
cell count dropping too low19.  As the CD4+ T-cells count decrease, symptoms such as persistent 
fever or diarrhea or recurrent yeast infections can begin to develop.  AIDS is the final stage of 
HIV infection, and is classified by plasma CD4+ T-cell count <200 cells/mm3.  A IDS is 
characterized by a series of opportunistic infections, or infections that are typically not seen in 
individuals with healthy immune systems. These infections include, but are not limited to 
cytomegalovirus, Kaposi’s sarcoma, pneumocystis carinii pneumonia (PCP), and 
histoplasmosis5.  Currently, there is no cure for HIV, and all individuals who are diagnosed with 
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HIV will eventually develop AIDS and die as a result of infections caused by a severely 
compromised immune system. 
1.2.4 Antiretroviral Therapy and HIV 
Following the initial cases of HIV, a need quickly emerged for medications to help suppress HIV 
infection and delay or prevent the onset of AIDS.  P rior to the introduction of HIV-specific 
medications, AIDS was treated by managing the symptoms and complications associated with 
the various opportunistic infections.  In 1985 zidovudine (ZDV), originally developed in 1964 as 
a drug to help treat cancer caused by viruses, was first described to have antiretroviral activity 
against HIV22.  A randomized clinical trial of ZDV found that the drug was able to prolong the 
life of patients with AIDS and in 1987 t he drug was approved for clinical use23.   T his 
breakthrough was the first step in a long history of developing new drugs to target HIV and treat 
AIDS. 
In 1996, a new approach was taken to treating HIV by combining multiple antiretroviral 
medications.  Called highly active antiretroviral therapy (HAART), this method typically uses 
three different antiretroviral medications, sometimes referred to as a ‘cocktail’.24  Today, some 
drug combinations of several antiretroviral agents are considered the standard of care for 
individuals with HIV22. Since its introduction, HAART has had many successes but has also 
created some unique issues for individuals with HIV.   
As a result of the successful integration of combination therapy as the standard of care for 
individuals with HIV, there has been a disappearance of the majority of the signs and symptoms 
of HIV, and the incidence of many AIDS related opportunistic infections has also decreased.  An 
individual taking HAART has a reduced risk of transmitting the virus to others, which can 
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increase quality of life and improve relationships.   O ne of the major successes of HAART 
therapy has been the transition of HIV from an acute disease to a chronic disease that requires 
lifelong management.   
Prior to the introduction of antiretroviral therapy, the average lifespan following 
diagnosis was only 7 years6.  In a study done looking at the records of over 7,000 HIV-positive 
patients treated in 18 different centers across the United States, the average life expectancy in 
2006 was more than 20 years6. It is now thought that an individual with HIV who is treated with 
HAART therapy will have a lifespan that is close to an individual in the general population.  
In spite of these achievements, there have also been some drawbacks associated with 
HAART.  M any individuals still suffer from anxiety and depression following their HIV 
diagnosis, regardless of how successful HAART is in managing their disease.   HAART has also  
been associated with long-term physical side effects, such as increased blood pressure, elevated 
cholesterol levels, redistributions of fatty tissue, increased risk for insulin resistant diabetes, and 
peripheral neuropathy.  These adverse effects can have a n egative impact on a p erson’s self 
image and relationships with others.5  Finally, the demanding medication schedule, adverse drug 
reactions, and unpleasant side effects can lead to difficulties in adhering to HAART 18.  Strict 
adherence is important to help avoid the development of viral resistance to a p articular 
medication or class of medications.  If resistance develops, one option is to replace the 
medication with another anti-HIV compound24. 
In 2008, there were 25 anti-HIV compounds licensed for the treatment of AIDS18, 22.  
These compounds can be classified into categories depending on what part of the HIV life cycle 
they target. A table summarizing the different types of HIV medications can be seen in Table 1. 
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Table 1:  Classes of HIV Medications22 
Class of Drug Method of Action 
Nucleoside reverse transcriptase inhibitors (NRTIs) Inhibit Reverse Transcriptase 
Nucleotide reverse transcriptase inhibitors (NtRTIs) Inhibit Reverse Transcriptase 
Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) 
Inhibit Reverse Transcriptase 
Protease inhibitors Inhibit HIV Protease 
Integrase Inhibitors Inhibit HIV Integrase 
Entry inhibitors (fusion inhibitors) Prevent virus from fusing and entering target cells. 
CCR5 Receptor antagonists 
Bind to CCR5 receptors on T-cells and block viral 
attachment 
Maturation inhibitors Prevent processing of viral proteins 
 
1.2.5 The Shifting Epidemiology of HIV in the United States – Impact on Women 
During the first decade of the HIV epidemic, steady and sharp increases were observed in the 
incidence of HIV/AIDS25.  T he disease during this time was characterized as an illness in 
Caucasian MSM, the group in which the AIDS was first recognized.  O ther at risk groups, 
including intravenous drug users, heterosexual males, and women accounted for approximately 
33% of the total incident cases of HIV infection.  T he HIV Epidemic peaked in 1993 w hen 
80,000 new infections were reported. In 1995, the death rate due to AIDS reached its peak, 
accounting for 2% of all deaths in the United States.  During this time, AIDS was the leading 
cause of death in men and women 25 to 44 years of age and was the 8th leading cause of death 
overall.25, 26 
Following 1993, t he incidence rates of HIV/AIDS began to decrease, likely due to the 
introduction and successful use of antiretroviral drug therapy and prophylactic treatment with 
Bactrim to prevent PCP.  O ther factors, such as increased use of primary protection and 
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prophylactic medications for opportunistic infections also likely contributed to the lower 
incidence rates of HIV.   From 1998 to 2007, the rates of HIV infection stabilized, with 40,000 
new infections being reported every year25, 26.  Despite falling incidence rates, prevalence rates 
have steadily increased as a result of decreased morbidity and mortality associated with HIV.  
Figure 2 summarizes the trends for AIDS from 1985 to 2007.   In 2007, it was estimated that 1.2 
million people were living with HIV and 450,000 people were living with AIDS in the United 
States25, 26.  In 2009, the CDC estimated that an additional 35,000 were diagnosed with AIDS26. 
 
 
Figure 2:  Characteristics of the AIDS Epidemic in the United States:  1985-2007 26                      
Copyright Permissions Received 
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In addition to shifting rates of infection, the epidemic has also changed in terms of groups 
at risk.  A s the epidemic continued, the rates of infection increased for heterosexual men, 
minorities, and women27.  Because the focus of this thesis is HIV infection in pregnant women, 
the growing epidemic in women will be the primary focus of the following discussion. 
In 1985, w omen accounted for 8% of the total number of individuals diagnosed with 
AIDS. Over time, the proportion of the total epidemic represented by women has increased 
dramatically.  In 2008, it was estimated that 26% of new AIDS diagnoses were in women2.  The 
progression of women in relation to the total AIDS disease burden can be seen in Figure 3.   
 
 
Figure 3:  The Proportion of Women in the AIDS Epidemic:  1985-20082                              
Copyright Permissions Received 
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 Using extended back calculation methods, Hall et al. estimated the incidence rate of HIV 
infection for men and women in the United States from 1980-2006.  The rates of infection in 
women began to increase in the late 1980s and have remained constant, whereas the rate of 
infection in men decreased dramatically and stabilized over the same time period27.  
In 2006, it was estimated that 15,000 new cases of HIV were diagnosed in women in the 
United States and 280,000 women were living with HIV/AIDS2, 27.  Eighty percent of these cases 
are due to high-risk heterosexual contact, whereas the remaining 20% are due to intravenous 
drug use, a combination of high-risk heterosexual contact and intravenous drug use, or other 
factors3.  
HIV-positive minority women represent the majority of the incident AIDS disease 
burden2.   W hen comparing the percentages of minority women belonging to minority groups 
being diagnosed with AIDS to the total percentages in the general population, there are dramatic 
differences.  African-American women make up the majority of diagnoses of AIDS, 65%, but 
only 12% of the total population of women in the United States.  T his is in comparison to 
Caucasian women, who make up 16% of new AIDS diagnoses, but account for 68% of the total 
population of women in the United States.  The proportion of AIDS diagnoses and percentages 
of the total population for Latina women and all other ethnic groups are more comparable, at 
17% and 13% for Latinas and 3% and 7% for other ethnic groups, respectively. 
The majority of women living with HIV/AIDS are of reproductive age.  For women of all 
races and ethnicities, the largest number of HIV/AIDS diagnoses during recent years were in 
women of childbearing age, between the ages of 15 a nd 393.  Because the majority of newly 
diagnosed women are within their childbearing years, the decision to bear children is an issue 
that many HIV-positive women consider.  Increases in lifespan and successful medication 
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regimens that reduce the risk of perinatal transmission have impacted the pregnancy rates among 
HIV-positive women in the United States28.  
In 1994, pr ior to the introduction of antiretroviral therapy for HIV-positive pregnant 
women, 14% of women who were HIV-positive were becoming pregnant annually.28.  A study 
by Blair et al. in 2004 examined the pregnancy rates among HIV-positive women following the 
introduction of ZDV and HAART.  The results of  this study can be seen in Figure 4.  
 
 
Figure 4:  Pregnancy Rates in HIV-positive Women: 1992-200128    
Copyright Permissions Received  
 
 Following the introduction of HAART in 1996, the rates of pregnancy increased in HIV-
positive pregnant women from 4 pregnancies per 100 person-years to 6 per 100 person years28, 29.  
Consistent with this study, a study by Sharma et al. showed that the live birth rate was 150% 
higher among HIV-positive women following the introduction of HAART as compared to birth 
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rates in the pre-HAART era30.  The rates were higher among women of all age groups, but the 
largest differences were seen in women older than 3530.  Studies have also shown that in addition 
to an increase in the number of women who are choosing to become pregnant, these same 
women are more likely to carry their pregnancy to term rather than choosing an elective 
termination29. The CDC estimates that every year, between 6,000 and 7,000 H IV-positive 
women will become pregnant3, 9, 31.  
As the numbers of women living with HIV/AIDS in the United States continue to 
increase, the number of HIV-positive pregnant women can also expect to increase.   A s more 
HIV positive women become pregnant, it becomes more likely that these same women will be 
referred to prenatal genetic counseling for matters unrelated to their HIV infection.  
1.3 GENETIC COUNSELING 
1.3.1 What is Genetic Counseling? 
Genetic counseling is the process of helping people understand and adapt to the medical, 
psychological, and familial implications of genetic contributions of disease32.  T he process of 
genetic counseling integrates “interpretation of family and medical histories to assess the chance 
of disease occurrence or recurrence, education about inheritance, testing, management, 
prevention, resources, and research, and counseling to promote informed choices and adaptation 
to the risk or condition”.32  Genetic counselors work with physicians, nurses, social workers, and 
other members of the health care team to help provide quality care to patients.   
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1.3.1.1 Principles and Goals of Genetic Counseling 
Genetic counselors practice under a number of assumptions or principles which are 
important to the profession.  S ome of these tenets are voluntary utilization of services, equal 
access, client education, complete disclosure of information, nondirective counseling, attention 
to psychosocial and affective dimensions in counseling, and confidentiality and protection of 
privacy.32   
Genetic counselors believe that the utilization of genetic services is a choice that should 
be made by the patient.  Patients are not forced to meet with genetic counselors and should not 
feel as though they are being irresponsible if they decline the services provided by such 
professionals.  At the same time, however, it is important that all individuals have the option of 
pursuing genetic counseling.  E qual access to services provided by genetic counselors is the 
ideal.  H owever, it is documented that people who live in urban settings, people with health 
insurance, and people with higher education are more likely to seek genetic counseling compared 
to other individuals.  Measures have been taken to reduce this discrepancy by expanding genetic 
counseling services to rural areas, lower-income populations, and to individuals who might 
otherwise not be aware, or identify the need for services.     
One of the most important parts of a genetic counseling session is client education and 
disclosure of information.   A  genetic counselor’s role is to provide patients with the most 
accurate and detailed information necessary to allow the patient to make an informed decision.  
The education provided within a session is usually extensive, and typically covers the features, 
natural history, and range of variability of the condition in question, the genetic (or nongenetic) 
basis, how it is diagnosed, the clinical management, the risk of occurrence or recurrence in 
family members, economic, social, and psychological impact, challenges it presents, prevention 
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strategies, and relevant research to increase the understanding of the disorder.32  Genetic 
counselors are responsible for providing the most accurate and relevant information possible to 
patients.   “Being selective in what one tells a client is viewed as paternalistic – and disrespectful 
of the person’s autonomy and competence”.32  Providing a client with information should not be 
confused with an attempt to influence a client’s decision, because this conflicts with genetic 
counselors’ approach that counseling should be non-directive. 
It has been discussed in the literature that adherence to nondirective counseling is the 
most defining feature of genetic counseling32.  Information provided by a genetic counselor 
should be presented in a nonbiased and fair manner without an attempt to influence an individual 
towards a particular decision.  N ondirective counseling can be difficult in some situations, 
however it is the genetic counselor’s role to help guide an individual through the decision 
process that is most appropriate for them.32   
Delivery of information does not necessarily promote an informed decision-making 
process.  Each individual has a combination of social, cultural, educational, economic, emotional 
and environmental circumstances that influence the decision-making process. Learning about 
genetic or reproductive risks can create strong emotional reactions.  A crucial part of genetic 
counseling is recognizing the possible occurrences of these reactions, and helping patients 
anticipate and make plans for how to deal with these emotions.32  A skilled genetic counselor 
will be able to listen effectively and identify key issues which are important to a patient while 
exploring a patient’s personal interpretation of the information and risks presented to them.32   
Information which may be discussed in a genetic counseling session may be highly personal or 
private, and patients should be assured that all information will be kept strictly confidential. 
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Although patient confidentiality has always been an important part of genetic counseling, 
the passage of The Health Insurance Privacy and Accountability Act (HIPAA) in 1996 
formalized a patient’s rights to privacy.   Genetic information is a highly sensitive and personal 
subject, and patients should be assured that unless direct permission is given, genetic counselors 
cannot share information with anyone, even other family members.   A dditional information 
shared in sessions is also kept confidential, regardless of its genetic relevancy or not.   
In order to gain competency in these principles, genetic counselors must successfully 
complete training which is outlined by the American Society of Genetic Counselors (ABGC).   
1.3.1.2 Training Programs for Genetic Counselors 
Currently, genetic counseling training requires the completion of an undergraduate 
degree followed by a two-year master’s degree program.  Prior to the establishment of formal 
training programs, genetic counseling was completed by nurses, social workers, physicians, or 
individuals who had undergraduate degrees in genetics32.  T oday, the majority of genetic 
counselors have masters of science degrees, although some counselors choose to pursue 
additional degrees in nursing, social work, public health, and business33.   
The first genetic counseling program was started in 1969 at Sarah Lawrence College.  
Since then, over 30 programs have been established in the United States and Canada.  There are 
currently 32 accredited genetic counseling programs recognized by the American Board of 
Genetic Counselors in the United States and Canada.  These programs vary in number of 
students taken, affiliation with other institutions (graduate schools, medical schools, schools of 
public health, etc.), and curriculum.  A list of the current genetic counseling programs in the 
United States and Canada can be found at www.abgc.net. 
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Genetic counseling training programs use a combination of traditional classroom learning 
and clinical internships to educate their students regarding the different roles of genetic 
counselors.  
1.3.1.3 Prenatal Genetic Counseling 
The practical scope of genetic counseling has grown since its introduction.  Genetic 
counselors practice in a variety of settings and serve a diverse patient population.  According to 
the National Board of Genetic Counselors, 83% of genetic counselors work in a clinical setting, 
meaning that they interact with patients on a regular basis.  As the field of genetic counseling has 
grown, the areas of practice for genetic counselors have also expanded.  There are currently over 
two dozen specialty areas for genetic counseling, but the majority of counselors still identify 
prenatal genetic counseling as their primary area of focus.33   
Prenatal genetic counseling focuses on pr oviding services for pregnant women, their 
partners, and their families.  Women who seek prenatal genetic counseling may be referred for a 
variety of reasons, some of which are not truly genetic indications.  Table 2 provides examples of 
some reasons why women would be referred to prenatal genetic counseling. 
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Table 2:  Common Reasons for Referral to Prenatal Genetic Counseling34-36 
Reason for Referral Comment 
Advanced Maternal Age (>35) 
Increased risk for chromosome conditions like Down 
syndrome, Trisomy 18, or Trisomy 13 
Personal/family history of a genetic condition Increased risk of passing on genetic condition 
Previous child with genetic condition or birth defect 
Increased risk of recurrence for genetic 
condition/birth defect 
High-risk ethnic background 
Increased carrier risk for conditions specific to ethnic 
backgrounds 
• Cystic Fibrosis in the Caucasian population 
• Sickle Cell Anemia in the African-American 
population 
• Tay-Sachs in the Ashkenazi Jewish 
population 
Multiple Miscarriages (>3) 
Increased risk of a genetic cause for recurrent 
miscarriages 
Consanguinity (pregnancy between two individuals 
more closely related than 2nd cousins) 
Increased risk for birth defects or recessive 
conditions 
Women with ‘high risk’ medical conditions 
Examples:  Diabetes, hypothyroidism, 
phenylketonuria 
Exposure to drugs or alcohol during the pregnancy 
Increased risk for pregnancy complications, birth 
defects, withdrawal following delivery, and long-term 
adverse effects to the child 
Exposure to medications during pregnancy known to 
be associated with birth defects or adverse fetal 
outcomes 
Increased risk for miscarriage/stillbirth, birth 
defects, or complications following delivery 
Maternal viral, bacterial, or protozoal infections 
during pregnancy 
Increased risk for miscarriage/stillbirth, birth 
defects, complications following delivery, and fetal 
infection. 
 
During a prenatal genetic counseling session, counselors will collect a family history, 
perform a risk assessment, and discuss different testing options available for the parents and the 
fetus to help clarify specific risks.  M aternal serum screening tests are one option that use a 
combination of ultrasound and maternal blood work generate personalized risk estimates for 
Down syndrome and Trisomy 18.  These tests are not diagnostic, however.  Diagnostic options 
for couples with risks for birth defects or chromosome conditions include diagnostic ultrasound 
and early invasive diagnostic procedures.   Diagnostic ultrasound is done during the second 
trimester and uses ultrasound to look for physical signs birth defects which may be associated 
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with genetic conditions or chromosome abnormalities.  These detailed anatomical ultrasounds 
are able to detect about 50% of cases of Down syndrome, 90% of cases of Trisomy 13 and 18, 
and 95% of cases of spina bifida.  In addition to looking for these conditions, diagnostic 
ultrasounds can also detect structural birth defects such as congenital heart defects or brain 
malformations.  Diagnostic tests include the early invasive procedures such as chorionic villus 
sampling and amniocentesis.  These tests collect fetal tissue or cells to allow for direct testing for 
conditions of interest.  These procedures are able to confirm the presence of a chromosome 
abnormality with greater than 99% accuracy and can also be used for genetic testing for specific 
conditions of interest if parental mutations are known.  Because chorionic villus sampling and 
amniocentesis are invasive procedures, they carry a 1 in 1000 r isk of complications that could 
result in miscarriage.  It sometimes may be necessary to do genetic testing on one or both parents 
check for underlying chromosome changes or genetic conditions which might put the pregnancy 
at risk. Prenatal genetic counselors describe the different options available to women/couples to 
help understand and personalize risks, discuss the benefits and limitations of each option, and 
help women and their partners work through the decision-making process to choose the option 
that works best for them. 34     
If a genetic condition or birth defect is identified in a pregnancy, genetic counselors work 
with families to help them make decisions about the outcome of the pregnancy.  Potential options 
include continuing the pregnancy with intention to keep the baby, giving the baby up f or 
adoption following delivery, or elective termination of the pregnancy.  If a chromosome change 
is identified or an underlying genetic condition is identified in a parent, couples can be counseled 
regarding fertility options, including chorionic villus sampling/amniocentesis, preconception 
genetic diagnosis, adoption, or the use of a donor sperm/egg to help reduce the risks of having a 
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child with an unbalanced chromosome abnormality.34  Counselors are also useful in these 
situations to provide psychosocial counseling for issues that can arise from diagnosing and 
managing an at-risk pregnancy37 . 
As discussed, there are many reasons a woman might be referred for prenatal genetic 
counseling.  It is not uncommon for many women to fall into more than one of these categories.  
Although HIV is not a true genetic condition which would warrant genetic counseling, it is a 
relevant part of a woman’s medical history and can have implications on m anagement during 
pregnancy.  Women with HIV are not just women with HIV, they are women who are being 
referred for counseling due to advanced maternal age, genetic risks, medication exposures, and 
any other of reasons that a women without HIV would be referred to genetic counseling.  HIV-
positive pregnant women have unique medical and psychosocial issues which may be relevant 
topics of discussion during a prenatal genetic counseling session.  The next section of this thesis 
examines these issues in more detail. 
1.4 HIV AND PREGNANCY AND GENETIC COUNSELING:  TOPICS OF 
CONCERN 
1.4.1 HIV Perinatal Transmission Risks 
HIV infection during pregnancy has not been found to have detrimental effects on the health of 
the mother and has not been associated with an increased risk for miscarriage29, 31  The major 
risks for infants born to mothers with HIV are the risks associated with perinatal infection.    
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Perinatal transmission is the most common way for children to become infected with 
HIV9.  HIV varies from other vertically transmitted pathogens because it is able to be transmitted 
to infants during pregnancy (in utero exposure), labor and delivery (intrapartum exposure), and 
breastfeeding38.   
The majority of in utero transmission of HIV occurs during the third trimester of 
pregnancy, although fetal infection has been reported during the first two trimesters38.  The most 
likely mode of transmission is due to HIV crossing the placenta from microtransfusion of 
maternal blood across the placenta39.  In the absence of intervention, the risk of transmission for 
in utero exposure is 5-10%39.  HIV-related risk factors associated with in utero transmission are 
the mother’s HIV plasma viral load and CD4+ T-cell count.  T he risk of transmission during 
pregnancy is greater in women with higher HIV plasma loads and studies have shown that a low 
maternal CD4+ T-cell count (<500cells/mm3) is also associated with increased rates of 
transmission39.  A dditional risk factors include infections during pregnancy such as common 
bacterial infections or sexually transmitted infections (STIs).38   To date, no l inks have been 
established between in utero transmission risks and maternal age, race or ethnicity, or history of 
a previously-infected child40. 
HIV transmission from mother-to-child is also possible during labor and delivery 
following exposure of the infant to contaminated maternal blood and genital secretions38.  
Among non-breast fed infants, the risk of infection during labor and delivery in untreated 
mothers is 10-20% and represents 66% of all perinatal infections.  S imilar to the transmission 
risks in utero, the higher the maternal plasma viral load, the higher the risk of infection for the 
infant.  Additional risk factors include prolonged duration of ruptured membranes (>4 hours) and 
vaginal lacerations that may occur during childbirth39.  In a study examining risks during labor 
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and delivery, the risk of infection increased by 2% for every hour the membranes remained 
ruptured.38, 39   
A final method of transmission from mother-to-child is from exposure to HIV through 
breastfeeding.  It is difficult to determine the exact transmission risks associated with 
breastfeeding because it is hard to separate these risks from exposures late in utero or during 
labor and delivery.  D espite these limitations, it is thought that 10-20% of infants who are 
breastfed from HIV-positive mothers will become infected.  Risk factors for transmission include 
duration of breastfeeding and maternal plasma viral load.  Viral load in breast milk is decreased 
approximately 2-3 log10 as compared to plasma and each 10-fold increase of viral RNA in breast 
milk is associated with a 2 fold increase in transmission.38 
Combining the risks associated with in utero, intrapartum, and breastfeeding exposures, 
the risk of an exposed infant to become infected with HIV is approximately 30-45% in the 
absence of interventions.  Successful intervention strategies include successful treatment with 
antiretroviral medications, obstetric interventions, and alternatives to breastfeeding38. 
1.4.2 Management During Pregnancy 
1.4.2.1 Recommended medications and risks associated with medications 
Successful use and adherence to antiretroviral medications has been shown to reduce the 
risks associated with mother-to-child transmission of HIV.  In 1994 i t was shown that short-
course regimens of ZDV were able to reduce the incidence of vertical transmission of HIV by 
15-20%. ZDV is able to cross the placenta and is thought to reduce the maternal HIV viral load 
and provide prophylactic protection to the fetus during birth.  ZDV is not able to suppress the 
levels of virus in breast milk following birth, so treatment with ZDV alone does not lower the 
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transmission risks associated with breast feeding. In the United States, ZDV is still a commonly 
used antiretroviral medication in HAART regimens for HIV-positive pregnant women41. The 
current standard of care for HIV-positive women is to use a combination of three antiretroviral 
drugs from two or three different classes39.  T he introduction of additional antiretrovirals in 
combination with ZDV has lowered the rate of perinatal transmission to <2%39.   W hen to 
initiate therapy and what type of therapy to begin depends on s everal factors specific to the 
woman,  including her overall health, prior antiretroviral regimens, and the gestational age of the 
fetus at the first evaluation.  Table 3 discusses the recommendations for antiretroviral therapy for 
HIV-positive pregnant women in a variety of clinical situations.   
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Table 3:  Recommendations for Antiretroviral Drug Use for HIV-Positive Pregnant Women42 
Clinical Situation Recommendation 
HIV-infected woman 
who is receiving HAART 
and becomes pregnant 
 
Continue current HAART regimen if successfully suppressing viremia, except avoid 
use of efavirenz or other potentially teratogenic drugs in the first trimester and drugs 
with adverse potential for mother. 
 
In general, if the woman requires treatment, antiretroviral drugs should not be stopped 
during the 1st trimester. 
 
Cntinue HAART regimen during intrapartum period (ZDV given as continuous 
infusion during labor while other antiretroviral drugs are continued orally) and 
postpartum. 
 
HIV-infected woman on 
combination 
antiretroviral drug 
therapy who becomes 
pregnant 
 
In general, if the woman requires treatment, antiretroviral drugs should not be stopped 
during the first trimester or during pregnancy. 
 
Continue current combination antiretroviral therapy regimen if successfully 
suppressing viremia, however, avoid use of efavirenz or other potentially teratogenic 
drugs in the first trimester and drugs with known adverse potential for the mother. 
 
Perform HIV antiretroviral drug resistance testing if the woman has detectable viremia 
on therapy. 
 
Continue combination antiretroviral therapy regimen during intrapartum period (ZDV 
given as continuous infusion during labor while other antiretroviral agents are 
continued orally) and postpartum. 
 
HIV-infected pregnant 
woman who is 
antiretrovirals naïve and 
has indications for 
antiretroviral therapy 
 
Initiate HAART regimen. 
• Avoid use of Efavirenz or other potentially teratogenic drugs in the first 
trimester and drugs with known adverse potential for mother 
• Use of ZDV as a component of the antiretroviral regimen is recommended 
when feasible 
• Nevirapine can be used as a component of HAART for women with CD4+ 
count <250 cells/mm3 if the benefit clearly outweighs the risk due to an 
increased risk of severe hepatic toxicity 
 
For women who require immediate initiation of therapy for their own health, treatment 
should be initiated as soon as possible, including in the first trimester. 
 
Continue HAART regimen during intrapartum period (ZDV given as continuous 
infusion during labor while other antiretroviral agents are continued orally) and 
postpartum. 
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HIV-infected pregnant 
woman is antiretroviral 
naïve and does not 
require treatment for 
her own health 
 
HAART is recommended for prophylaxis of perinatal transmission in women who do 
not require treatment for their own health. 
• Consider delaying HAART initiation until after first trimester is completed 
• Avoid use of efavirenz or other potentially teratogenic drugs in the first 
trimester and drugs with known adverse potential for the mother 
• Use of ZDV as a component of the antiretroviral regiment is recommended 
when feasible 
• Nevirapine should only be used as a component of therapy in women with 
CD4+ counts <250 cells/mm3 if the benefit clearly outweighs the risk due to 
an increased risk of severe hepatic toxicity 
 
Use of ZDV prophylaxis alone is controversial but may be considered for those women 
with plasma HIV RNA levels <1000 copies/mL on no therapy. 
 
Continue HAART regimen during intrapartum period (ZDV given as continuous 
infusion during labor while other antiretroviral agents are continued orally). 
 
Evaluate need for continued therapy postpartum; discontinue HAART unless has 
indications for continued therapy. 
 
HIV-infected pregnant 
woman who is 
antiretroviral 
experienced but not 
currently receiving 
antiretroviral drugs 
 
Obtain full antiretroviral treatment history and evaluate need for antiretroviral 
treatment for own health. 
 
Initiate HAART, with regimen chosen based on resistance testing and prior history 
• Avoid use of efavirenz or other potentially teratogenic drugs in the first 
trimester and drugs with known adverse potential for the mother 
• Use of ZDV as a component of the antiretroviral regiment is recommended 
when feasible 
• Nevirapine should only be used as a component of therapy in women with 
CD4+ counts <250 cells/mm3 if the benefit clearly outweighs the risk due to 
an increased risk of severe hepatic toxicity 
 
Continue HAART regimen during intrapartum period (ZDV given as continuous 
infusion during labor while other antiretroviral agents are continued orally). 
 
Evaluate need for continued therapy postpartum; discontinue HAART unless has 
indications for continued therapy. 
 
HIV-infected woman 
who has received no 
antiretroviral therapy 
prior to labor 
 
ZDV given as continuous infusion during labor 
 
OR 
 
ZDV given as continuous infusion during labor, plus single dose nevirapine at onset of 
labor.  Consideration should be given to adding lamivudine during labor and maternal 
ZDV/lamivudine for 7 days postpartum, which may reduce development of nevirapine 
resistance. 
 
 
 
Table 3 Continued 
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For women undergoing Caesarian sections, it i s recommended that intravenous ZDV 
therapy begin 3 hou rs before the scheduled delivery41.  F or women delivering vaginally, 
intravenous ZDV should begin throughout labor and delivery42.   
A registry has been established to examine the risks for birth defects and negative 
pregnancy outcomes in women with HIV who are taking antiretroviral medications. The purpose 
of this registry is to “collect observational, nonexperimental data on the antiretroviral exposure 
during pregnancy for the purpose of assessing the potential teratogenicity” of antiretroviral 
medications43.   The Antiretroviral Pregnancy Registry has found that the risk for birth defects is 
5.8% for all women taking antiretrovirals during the first trimester, which is higher than 
observed in the general population.  Women taking antiretrovirals later in pregnancy have not 
had an increased risk for birth defects, and the risks are similar to those seen in the general 
population42.  When counseling HIV-positive pregnant women, it is important to keep these risks 
in mind and also to help weigh the risks versus the benefits of initiating or continuing 
antiretroviral use during the first trimester.39, 42  
   When deciding which medications should be used in a HAART regimen for an HIV-
positive pregnant woman, the FDA pregnancy categories for medications should be taken into 
consideration.  The majority of HIV medications are FDA category B or C, meaning that they 
can be considered for use during pregnancy without clear risks of associated birth defects11, 42.  
Some medications should not be used during pregnancy because of possible risks to the fetus or 
to the health of the mother. 
Efavirenz, a non-nucleoside reverse transcriptase inhibitor, is categorized by the FDA as 
a category D medication42.  Use of Efavirenz during the first trimester has been associated with 
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an increased risk for open neural tube defects, facial cleft defects, hydrocephalus, and 
anophthalmia (the congenital absence of one or both eyes).  Because there are alternative 
medications that HIV-positive pregnant women can consider for use during pregnancy in 
replacement of Efavirenz, it is recommended that its use be discontinued as soon as possible 
during the pregnancy42.   
Some additional antiretroviral medications are not recommended for use during 
pregnancy because of risks to the fetus. Zalcitabine has been associated with a high risk of 
hydrocephalus in rodents and Delavirdine has been associated with an increased risk for 
ventricular septal defects in rodents.  Although no human studies have been done to characterize 
the risk of birth defects, it is recommended that these medications be avoided.  Finally, tenoflovir 
has been associated with bone abnormalities in multiple species of lab animals.  Data from the 
antiretroviral pregnancy registry has shown a 2.66% risk of birth defects in women taking 
tenoflovir during the first trimester similar to those seen in the general population.  Despite these 
results, it is recommended that tenofovir should be used as a component of HAART only after 
alternatives have been ruled out.42 
Higher rates of preterm birth and low birth weight have been described in infants born to 
mothers who have taken antiretrovirals during pregnancy44.  In particular, it is thought that the 
use of protease inhibitors during pregnancy can lead to pregnancy complications.  R esults of 
studies examining pregnancy outcomes for women using antiretroviral therapy vary, and it is 
currently thought that some of the relationship between complications and antiretroviral 
exposure can be explained by the presence of additional risk factors.   In particular, low birth 
weight and preterm delivery have been associated with race/ethnicity, substance abuse, parity, 
prior preterm birth, hypertension, maternal diabetes, low maternal weight, and poor prenatal 
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care44.  Women with HIV should be supervised appropriately during pregnancy according to risk 
factors and indications from prenatal ultrasound to help manage the risks for complications such 
as low birth weight and preterm delivery. 
One medication, nevirapine, was initially used in combination with ZDV to treat women 
with HIV during pregnancy. It is now known that nevirapine may not be recommended in 
women with CD4+ T-cell counts >250 cells/mm3 because of adverse effects for the mother, 
specifically hepatotoxicity39, 41.   
For more information on t he safety of the use of antiretroviral medications during 
pregnancy and the current antiretroviral combination recommendations, the Public Health 
Service Task Force guide, “Recommendations for use of antiretroviral drugs in pregnant HIV-
infected women for Maternal Health and Interventions to Reduce Perinatal transmission in the 
United States” is useful.   Information regarding the Antiretroviral Pregnancy Registry can be 
found at http://www.APRegistry.com. 
1.4.2.2 Obstetric Management for HIV-positive Pregnant Women 
Women with HIV should undergo traditional prenatal health care as well as some 
additional assessments to help characterize the status of their infection and to determine what 
treatment methods should be utilized42.  In addition to the standard antenatal assessments for all 
pregnant women, the initial evaluation should include evaluation of CD4+ T-cell count, plasma 
viral load, complete blood count, and renal and liver function tests.  It is also important to get an 
accurate medical history for the mother including history of prior and current antiretroviral 
treatment, history of prior antiretroviral drug use to prevent perinatal transmission in a prior 
pregnancy, results of prior and current antiretroviral drug resistance testing, and an assessment of 
additional supportive care needs42.  Continual monitoring of the mother’s viral load and CD4+ T-
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cell count is an important component of maternal care and should be measured every 3 months 
following the initial visit.  V iral load should be checked 2-6 weeks following initiation or 
alteration of antiretroviral therapy and then monthly  until undetectable.  If viral load becomes 
undetectable, it should still be monitored at least every 2 months during pregnancy.11, 42 
Just as important as initiating antiretroviral therapy is the monitoring of the mother for 
adverse side effects which may impact her ability to continue therapy.  M onitoring for 
complications from therapy should be done throughout pregnancy and changes should be made 
as necessary.   In addition, it is  recommended that both first trimester and second trimester 
ultrasound be done to identify any birth defects or pregnancy complications that could be a result 
of antiretroviral therapy.42 
HIV-positive pregnant women who choose to undergo maternal serum screening tests 
should be aware that their HIV infection may impact the results of the testing . Maternal serum 
screening tests for Down Syndrome and Trisomy 18 are available during the first and second 
trimester.  The first trimester test uses a combination of maternal serum testing for two chemicals 
produced by the pregnancy (human chorionic gonadotrophin and pregnancy-associated plasma 
protein) as well as ultrasound measurement of the nuchal translucency to generate a risk estimate 
for both Down syndrome and Trisomy 1845.  A  study examining first trimester screening 
outcomes found that a woman’s HIV status decreases the values of both chemicals analyzed, but 
does not impact the overall risk estimate generated for these women45.   
Second trimester maternal serum screening is called the quad screen, and uses a 
combination of four chemicals produced by the pregnancy (alpha-fetoprotein, human chorionic 
gonadotropin, estriol, and inhibin-A) to estimate the risks for Down syndrome, Trisomy 18, and 
spina bifida46.  The quad screen has been found to have a false positive rate of 5% in the general 
 33 
population.  S tudies examining the results of the quad screen in HIV-positive women have 
shown that the screen-positive rate is as high as 33% compared to 5% in the general 
population46.   Specifically, maternal serum levels of human chorionic gonadotrophin have been 
found to be significantly increased in women with HIV, which may explain the higher rate of 
false positives46.  A n explanation for this increased false positive rate has not yet been 
determined, although some studies have suggested that certain types of antiretroviral therapy and 
CD4+ T-cell counts may impact the measurement of these chemicals during pregnancy46.   
Because the results of the quad screen may be difficult to interpret for HIV-positive women, it is 
recommended that they undergo the first trimester screen or detailed second trimester ultrasound 
to assess for fetal abnormalities associated with chromosome conditions46.  In the case where a 
woman’s risk is elevated for a chromosome condition these women may consider the option of 
early invasive diagnostic testing.   
HIV-positive pregnant women may consider the option of early invasive diagnostic 
techniques like chorionic villus sampling or amniocentesis because of advanced maternal age, 
elevated maternal serum screening test results, clarification of the cause of birth defects detected 
on ultrasound, or because of a risk of a genetic condition47.  P rior to the introduction of 
antiretroviral therapy, early invasive procedures were associated with high risks of vertical 
infection.  T wo independent studies done in the 1990s found that the risk for mother-to-child 
transmission following early invasive procedures was  greater than 36%47. It is important to note 
that these studies were done prior to the widespread use of HAART during pregnancy.  In 2005, 
a study examined the pregnancy outcomes of 63 w omen who underwent early invasive 
diagnostic techniques. They found that 3.3% of infants born to these women were infected with 
HIV upon delivery, which was not statistically different from infants born to mothers who did 
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not have invasive diagnostic procedures done during pregnancy47.  This is reassuring for HIV-
positive pregnant women, although it is recommended that women with HIV consider these 
procedures only if they have undetectable viral loads and are receiving antiretroviral therapy.   
1.4.2.3 Delivery Options for HIV-positive Pregnant Women 
One of the major management decisions that must be made for women with HIV is 
whether to deliver the baby through vaginal delivery or by Caesarian section.  Elective cesarean 
section delivery prior to the onset of labor has been shown to reduce the risk of HIV transmission 
by 50% when compared to women who delivered vaginally41.  An important consideration is that 
the Caesarian section must be elective – meaning that the membranes have not ruptured prior to 
the initiation of the procedure.  T he rates of transmission have been found to be similar in 
women who deliver vaginally and in women who delver via Caesarian section following the 
onset of labor.  Although it is difficult to prove conclusively, it is thought that the labor process 
is responsible for a considerable amount of intrapartum infections41.  The majority of studies 
looking at transmission rates when comparing modes of delivery were done prior to the 
introduction of combination therapy as the standard of care for HIV-positive pregnant women.  
Recent studies show that the risk to transmit HIV following a C aesarian section or vaginal 
delivery in a mother who has been managed with HAART is not significantly different, 
approximately 1.8% and 2.0% respectively41.  In the United States it is recommended that a viral 
load test be done at 34-36 weeks of pregnancy to help guide decisions regarding the mode of 
delivery.  The American College of Obstetricians and Gynecologists Committee on Obstetric 
Practice recommend that women with viral loads >1000 copies/mm3 be offered a Caesarian 
section39.  If the viral load is <1000 copies/mm3, however, the mother can decide whether or not 
she prefers vaginal delivery or Caesarian section39, 41.  
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1.4.2.4 Alternatives to Breastfeeding 
Because of the risks associated with breastfeeding and transmission of HIV, it is  
recommended that all HIV-positive women avoid breastfeeding whenever possible41.  Even for 
HIV-positive women are receiving antiretroviral therapy, breastfeeding is not considered safe 
and alternative methods should be identified39.  In the United States and other developed 
countries, safe and sustainable alternatives to breastfeeding are available because of the 
accessibility to formula foods and clean water supplies48.   
An important consideration when discussing alternatives to breastfeeding may be the 
cultural implications of its absence.  In some cultures, it is expected that women will breastfeed, 
and this may pose difficulties for women with HIV.  Expectations from family members, friends, 
and larger social groups may make the decision to use alternative methods to breastfeeding 
difficult.  Health care providers should provide support and resources to aid these women in  
explaining why it is important to consider alternatives to breastfeeding.49 
1.4.2.5 Management for Children Following Birth 
Infants born to HIV-positive women also require specialized management during their 
first weeks of life.  Continuation of antiretroviral medications is important and it is  
recommended that all HIV-exposed infants receive ZDV for 6 w eeks following delivery42, 50.  
Ideally, the first dose should be given within the first 12 hours of life42.  Infants taking ZDV may 
be at a higher risk to develop anemia compared to other infants, and close monitoring for signs of 
anemia should be done while the infant is taking ZDV42.   L ong-term effects of antiretroviral 
medications on infants born to HIV-positive mothers following in utero exposure are not well 
characterized.  C onflicting reports have shown that some infants may suffer some degree of 
mitochondrial dysfunction following exposure, but these risks have not been confirmed42.   
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Another important component in the care for infants born to HIV-positive women is 
testing for HIV following delivery.   Because maternal antibodies for HIV are able to cross the 
placenta during pregnancy, antibody-based tests are not appropriate to diagnose HIV infection 
until after 18 m onths of age42.   I n children younger than 18 m onths, diagnosis is based on 
virological tests at 2-3 weeks, 1-2 months, and 4-6 months of age.  A  positive test requires 
follow-up with a second test to confirm positive status.  T wo positive HIV tests confirm the 
diagnosis.   Negative results are definitive in infants who have two negative tests done after 1 
month and after 4 months of age respectively42.  Finally, all infants, regardless of their initial test 
results, should have antibody titers drawn for HIV at age 18 months for confirmatory diagnosis.50   
Following birth, all HIV exposed infants should have a detailed physical examination42. 
Because infection cannot be ruled out completely in infants until the age of 18 m onths, some 
prophylactic medications, like Bactrim, are also recommended to help prevent AIDS-related 
infections such as PCP.  Infants will often begin taking antibiotics between 4 and 6 weeks of age 
and continue taking them until an HIV diagnosis can be definitively ruled out or confirmed at 18 
months.50   
Finally, vaccination is an important part of care for all infants.  HIV exposed or infected 
infants that are asymptomatic should receive all recommended vaccinations on a  regular 
schedule.  For symptomatic infants with or those with documented immune suppression, a 
limited schedule of vaccinations should be given.  V aricella and oral polio vaccine should be 
avoided, but all other standard vaccines can be given without concern.  All children exposed to 
HIV, regardless of immune function or symptoms, should consider having Haemophilus 
Influenzae Type B and pneumococcal vaccines.50 
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1.4.3 The Impact on Transmission Risks following initiation of HAART and other 
Interventions 
As discussed, there are now several methods which can reduce the risks associated with perinatal 
transmission of HIV infection.  Rates of perinatal infection peaked in 1992, when it was 
estimated that 1650 c hildren born to HIV-positive mothers became infected with HIV in the 
United States9, 48.  After the introduction of antiretroviral therapy and HAART, these numbers 
have decreased, and in 2007 it was estimated that less than 200 children were diagnosed with 
HIV following perinatal exposure9, 10.  T he rates of AIDS diagnosis have also decreased, and 
these trends can be seen in Figure 5.   
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Figure 5:  Estimation of Perinatally Acquired AIDS Cases in the United States: 1985-20079   
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The rates of AIDS diagnoses also peaked in 1992, when approximately 855 children were 
diagnosed9, 10.  In 2005, 68 children were diagnosed with AIDS and 67 of them had been infected 
with HIV following perinatal exposure10.  D espite the decreases in both HIV and AIDA 
diagnoses from maternal to child transmission, children are still being infected following 
perinatal exposure.    The majority of these children are born to mothers who did not know they 
are HIV-positive48.    It is estimated that 25% of people who have HIV are not aware of their 
inefction12.  Routine screening for HIV during pregnancy can help reduce the number of children 
perinatally infected with HIV each year.   
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1.4.4 CDC Testing Recommendations for Pregnant Women 
1.4.4.1  Previous Testing Guidelines 
In 1995, the CDC first recommended HIV testing for all pregnant women.  The release of 
these guidelines coincided with the first reports that use of ZDV during pregnancy could 
decrease the risk of perinatal infection51.  The guidelines were developed to provide guidance for 
health-care workers when educating women about risks of perinatal HIV infection51.   
The 1995 guidelines recommended that health care providers counsel and encourage all 
pregnant women to undergo HIV testing as early in the pregnancy as possible.  The guidelines 
recommended that full pre-test counseling be conducted prior to testing and should include 
“information regarding the risk for HIV infection associated with sexual activity and injecting-
drug use, the risk for transmission to the woman’s infant if she is infected, and the availability of 
therapy to reduce this risk”.51  The recommendations stressed that testing should be voluntary, 
and consent should be obtained in writing.   Re-testing in the third trimester was recommended 
for women who practiced high-risk behaviors during the pregnancy.   
For women who presented during labor and delivery without prior prenatal care, the 1995 
recommendations suggested that these women undergo assessment for prior HIV testing, the 
results of these tests, and risk history.  The guidelines stressed that pre-test HIV counseling for 
these women be completed before testing.  If a child was born to a mother whose HIV status was 
unknown or to a mother who refused testing during pregnancy, the child should be tested as soon 
as possible following birth for HIV (with consent from the mother).  The recommendations note 
that mothers should be warned that such testing may implicate her HIV infection status, 
regardless of her decision to decline HIV testing.51   
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Following the release of the 1995 guidelines regarding testing and treatment for HIV 
during pregnancy, the rates of perinatal infection in the United States declined rapidly.  By 1999, 
the rates of perinatal infection had decreased by 83%40.  D espite the successes of these 
guidelines, they were not perfect, and infants were still being born to HIV-positive mothers who 
were not aware of their status.  A study conducted by the Institute of Medicine (IOM) in 1998 
found that “continued perinatal transmission was mainly caused by a lack of awareness of HIV 
status among some pregnant women.”40 Many women were declining testing because they 
thought their health-care providers did not strongly recommend it.  In addition, some providers 
did not offer testing because they perceived their patients at low risk, thought that the pre-test 
counseling process was too burdensome and time consuming, or misunderstood the requirements 
of counseling to obtain informed consent40.   The IOM recommended that HIV testing during 
pregnancy become universal, meaning that it should be offered to all women as part of the 
standard battery of prenatal tests, regardless of risk factors or the prevalence rate of HIV in the 
population40.  The IOM believed that such a transition to universal testing would avoid some of 
the stereotyping and stigma of socioeconomic or ethnic groups which might be perceived as 
high-risk by health care providers40. 
These recommendations led to the replacement of the 1995 guidelines in 2001.  The 2001 
guidelines published by the CDC emphasized universal HIV testing as a standard component of 
routine prenatal care. These new guidelines also simplified the pre-test counseling and informed 
consent processes.   H ealth-care providers were encouraged to recommend HIV testing to all 
pregnant patients as early in the pregnancy as possible, while providing the ‘minimum 
information’ necessary to obtain informed consent.  R equired topics that should be covered 
included: 
 41 
• HIV is the virus that causes AIDS.  HIV is spread through unprotected sexual contact and 
injection-drug use.  Approximately 25% of HIV-infected pregnant women who are not 
treated during pregnancy can transmit HIV to their infants during pregnancy, during labor 
and delivery, or through breast-feeding. 
• A woman might be at risk for HIV infection and not know it, even if she has had only one 
sex partner. 
• Effective interventions for HIV-infected pregnant women can protect their infants from 
acquiring HIV and can prolong the survival and improve the health of these mothers and 
their children. 
• For these reasons, HIV testing is recommended for all pregnant women. 
• Services are available to help women reduce their risk for HIV and to provide medical 
care and other assistance to those who are infected. 
• Women who decline testing will not be denied care for themselves or their infants. 40  
 
Under the 2001 recommendations, HIV testing was still a voluntary test and women had 
to ‘opt-in’ in order to have testing performed by obtaining documented informed consent.  The 
new guidelines stressed that if a w oman were to decline testing, health-care providers should 
address the reasons for declining, to build trust and rapport with the patient so they may choose 
to undergo testing at a later date40.   
Re-testing before 36 w eeks of gestation was recommended for women known to be at 
high-risk for acquiring HIV, including women who “have a history of sexually transmitted 
diseases, exchange sex for money or drugs, have multiple sex partners during pregnancy, use 
illicit drugs, have sex partners(s) known to be HIV-positive or at high risk, and have signs or 
symptoms of seroconversion”40.  Health care facilities with high rates of HIV among women of 
childbearing age were also recommended to do repeat HIV testing in the third trimester.   
For women who presented at labor and delivery with an unknown HIV status, the 2001 
guidelines recommended that rapid testing be done to determine her status so antiretroviral 
therapy could be initiated if required.  Informed consent of HIV testing during labor and delivery 
 42 
was required and women had to ‘opt-in’ to allow testing to be done.40  The recommendations for 
babies born to mothers with unknown HIV statuses did not change – the 2001 g uidelines 
recommended that these infants be tested (with the mother’s approval), although implications of 
test results should be explained to the mother with regard to her own HIV status.40   
These improvements from the 1995 guidelines made the testing process easier for many 
health care providers and resulted in an increased number of pregnant women being screened12.  
Despite these successes, certain populations of women were not being screened.  R easons for 
these women being missed were “language barriers, late entry into prenatal care, health care 
providers’ perceptions that their patients were at low risk for HIV, lack of time for counseling 
and testing (particularly for rapid testing during labor and delivery), and state regulations that 
required counseling and separate informed consent”12.    T o help address some of these issues, 
the CDC released updated recommendations for HIV testing in 2006. 
1.4.4.2 The 2006 CDC Testing Guidelines 
In September 2006, the CDC released “Revised Recommendations for HIV testing of 
Adults, Adolescents, and Pregnant Women in Health-Care Settings.”   These guidelines updated 
the 2001 r ecommendations for HIV screening during pregnancy and reiterated the suggestion 
that HIV screening be included universally as part of standard prenatal care.   It is important to 
recognize that the guidelines to vary depending on existing state regulations.   
The changes from the 2001-2006 guidelines are subtle, but further streamline the process 
of HIV screening during pregnancy.  The 2006 guidelines continue to recommend that all 
pregnant women be offered HIV screening as part of their standard prenatal care as early in the 
pregnancy in possible. HIV is now included in the standard battery of blood tests pregnant 
women receive at their first prenatal appointment.  Notification of HIV testing is still required, 
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however unless women actively decline testing, or “opt-out”, it will be performed.12  This is 
different from the 2001 guidelines that required an “opt-in” consent process.  It is still 
recommended that if a woman chooses to “opt-out” of HIV testing, her health care provider 
discuss the reasons for declining the test and address them to build trust and rapport so that in the 
future she may choose to consent to HIV testing.12   The 2006 guidelines recommend that rapid 
testing should be performed for all women in labor who have an undocumented HIV status.  In 
this setting, women should be notified that HIV testing is recommended for all pregnant women 
and that unless the patient actively declines, the testing will be doneThis again varies from the 
2001 guidelines which required an “opt-in” policy during labor and delivery.12 .  In some states, 
however, testing cannot be done without written consent of the mother.    Similar to the 2001 
guidelines, the 2006 recommendations support that women at high-risk should undergo a second 
HIV test during the third trimester.   A n additional group of women that should be tested are 
women who live in “jurisdictions with elevated HIV or AIDS incidence and for women receiving 
health care in facilities with at least one diagnosed HIV case per 1,000 pregnant women each 
year”.12 
The 2006 g uidelines are still in use today for all pregnant women.  T o help reinforce 
these recommendations, the CDC launched the “One Test, Two Lives Campaign” in 200848.  
This campaign strives to limit maternal transmission of HIV to their children and promote the 
health of mothers.   To help meet the goals of this campaign, educational materials have been 
developed for both pregnant women and healthcare providers addressing the importance of HIV 
testing during pregnancy.   W ith the release of these recommendations and programs like those 
discussed above, the numbers of healthcare providers routinely offering HIV testing to their 
patients during pregnancy is increasing.   
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A study conducted in 2006 found that 95-99% of providers reported routinely offering 
HIV testing to their patients who were pregnant with 64-89% of patients accepting testing52.  To 
further support these findings, a survey of women’s opinions on r outine HIV testing during 
pregnancy found that 90% of women agreed that HIV testing should be part of routine prenatal 
care52.   Despite these accomplishments, infants are still being born to women who do not know 
their HIV status.  To help identify infants who may have been exposed to HIV during pregnancy, 
some states are choosing to include HIV testing as part of newborn screening panels.  
1.4.5 Newborn Screening 
Every infant in the United States is screened for a variety of congenital conditions shortly 
following birth53.  The first newborn screen was developed in the 1960s to identify infants born 
with phenylketonuria, an inherited metabolic disorder.  Since then, newborn screening tests have 
been developed for dozens of conditions, the majority of which are genetic.  T o qualify as a 
condition that is included in the newborn screening panel, the condition must be able to be 
accurately screened for (have a low rate of false positives and false negatives), must have a 
treatment which can change the course of the disease, and must be cost-effective53.   
Newborn screening is a public health initiative that involves a coordinated process of 
testing, follow-up, diagnosis, disease management, and evaluation53.  C onditions screened for 
vary within states, the District of Columbia, and Puerto Rico. Currently, 21 conditions are 
required by law to be included in newborn screening panels53.  A dditional conditions can be 
added to panels by the discretion of individual states.  Efforts are being made, however, to 
increase the number of required conditions screened for using newborn screening to help 
standardize the test for all infants born within the United States53.    
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Some states have also began to incorporate HIV testing into their newborn screening 
panels.  As of January 2011, ten states currently offer HIV testing for infants.  Nevada, 
Mississippi, South Carolina, North Carolina, New Jersey, South Dakota, Wisconsin, Connecticut 
and Illinois offer HIV testing for all infants born to mothers without a documented HIV test 
result that was done during pregnancy.13  Rhode Island is also in the process of initiating a 
newborn screening program to test for HIV in infants born to mothers without a documented 
HIV test.  New York is the only state that routinely screens for HIV in all infants.54   
In 1987, New York State began screening all babies born within the state for HIV55.  The 
newborn screening tests check the infant’s blood for antibodies against HIV56.  If the child’s 
blood tests positive, this is proof that the child was exposed to HIV during pregnancy.  Infants 
with a positive HIV screening test should be started on ZDV as soon as possible to prevent 
infection.  Mothers of infants with positive HIV screening tests should be counseled about the 
results.  A positive test result in an infant indicates that the mother has HIV and for all intents 
and purposes involuntarily tests the mother.  If the HIV status was previously unknown, she 
should be evaluated to determine if she requires treatment to manage her condition and 
counseled to consider alternatives to breastfeeding.56  All infants with positive newborn 
screening HIV tests should be monitored according to accepted guidelines to confirm or rule out 
HIV infection. 
The CDC’s recommendations  that testing be done in infants born to mothers who have 
an undocumented HIV status may cause more states to include HIV on their newborn screening 
panel for either a subset or all infants.  Mandatory newborn screening will identify all infants 
exposed to HIV in pregnancy and allow for early treatment and decrease the odds of infection57.  
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In addition, routine newborn screening for HIV has been found to be cost-effective, even in areas 
where the prevalence of HIV is low57. 
1.4.6 Psychosocial Issues 
Women with HIV deal with unique psychosocial issues that are a result of their HIV infection. 
“When a woman contracts HIV infection, it does not occur in a vacuum; it occurs in the 
psychosocial context of a life with preexisting stresses within the woman’s social construct.”49 
Distrust, stigmatization, trauma, mental illness, and substance abuse are all psychosocial issues 
that have been associated with the diagnosis of HIV in women58.   For the HIV-positive pregnant 
woman, the impact of her HIV diagnosis as well as the pregnancy can lead to additional stresses 
and concerns that can exacerbate these psychosocial issues and create distinctive concerns for 
this demographic.58 
A distrust of medical services and health-care providers can be a major barrier to 
treatment for individuals living with HIV, especially women who are pregnant59.  Studies have 
shown that minority populations in general may have a greater distrust and are less likely to 
participate in clinical studies and treatment programs59.  When working with HIV-positive 
patients, health care providers must work to build trust to make the patient feel as comfortable as 
possible to increase compliance with treatment and management recommendations.   Health-care 
providers should treat every patient with respect and should not be condescending, patronizing, 
or judgmental.  In addition, a patient’s personal beliefs and cultural values should be respected 
and non-traditional treatment modalities should be complimented with traditional medical 
treatment, not replaced.20  Sensitivity when speaking with these patients is also crucial.  
“Responding to a patient’s fear, anxiety, denial, or anger is inevitably part of the health 
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provider’s role and requires consideration of more than a disease process, but of a whole person 
and the entire context of her life.”20   Finally, the patient should be reassured that the details of 
the visits are confidential and the information shared will not be discussed with anyone unless 
the patient grants permission.  Patients should be encouraged and assisted in disclosing their HIV 
status to important individuals like sexual partners and other health care providers. Some states 
require that HIV diagnoses be reported, and such regulations should be discussed with every 
patient.20 Confidentiality is important for individuals living with HIV because of the fear of 
discrimination and stigma that can result from an HIV diagnosis.   
Since the beginning of the outbreak, individuals with HIV have faced stigma regarding 
their diagnosis.  Much of this stigma revolves around society’s negative views that a person’s 
behaviors led to their becoming infected with HIV.49  This is particularly true for women because 
of the connotations with HIV infection, promiscuity, and prostitution20.   Stigma may be either 
experienced directly or perceived, but has been associated with negative impacts regarding 
antiretroviral adherence and increased risks for depression and risky sexual behavior59.  H IV-
positive women choosing to become pregnant may face additional stigmatization resulting in 
their decisions to have children.58  Family members and others within the community may view 
an HIV-positive woman’s decision to have a child as “reckless” or “self-serving”49.  For women 
who have not disclosed their status to family members or loved ones, the decision to disclose 
may be a difficult one.  W omen may fear abandonment, judgment, or violence following 
disclosure of their HIV status20.    
Trauma is relatively common among individuals with HIV and women with HIV are at 
an increased risk above men17.  Data from the HIV Costs and Service Utilization Study (HCSUS) 
found that 20.5% of women reported a physical assault by a partner or someone important to 
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them after becoming diagnosed with HIV59.  HIV-positive pregnant women may be at an 
increased risk for violence resulting from the disclosure of the infection status.  A study done in 
2009 indicated that 8.9% of pregnant women experienced recent violence.  Adjusting that to the 
rates of HIV-positive pregnant women, it was concluded that between 528 and 616 HIV-positive 
pregnant women are victims of violence while they are pregnant17.  Trauma and abuse have been 
associated with higher levels of mental illness and substance abuse in women with HIV.59 
Mental illness is a common finding in people living with HIV.  The HCSUS indicated 
that as many as 48% of people surveyed had probable psychiatric disorders59.  Depression is one 
of the most common mental illnesses present among people living with HIV.  S tudies suggest 
that the rate of major depressive disorder is 10 t imes higher in HIV-positive persons than in 
persons who are not HIV infected.  For women specifically, it is thought that 40% of women 
living with HIV suffer from symptoms of depression and 50.3% of HIV-positive women who are 
pregnant are depressed.20, 58  
Depression is associated with adverse outcomes in pregnancy, including low birth 
weight, preterm labor, and an increased risk for post-partum depression.  For women living with 
HIV, depression is “the most robust predictor of non-adherence” for antiretroviral regimens.  As 
discussed previously, antiretroviral therapy during pregnancy is a crucial part of prevention of 
maternal to child transmission as well as prevention of resistant strains of HIV.58  In addition to 
non-adherence, depression has been reported by HIV-positive pregnant women as a reason why 
some choose to postpone or not receive prenatal care.  Careful assessment and consideration of 
treatment for depression during pregnancy is important for HIV-positive women.   B ecause 
women with HIV are already exposing their infants to a v ariety of medications during 
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pregnancy, it has been recommended that HIV-positive pregnant women consider counseling or 
psychotherapy to help manage their symptoms of depression before medications are prescribed.   
Substance abuse represents a co -morbidity related to HIV58.  In 2002, i t was estimated 
that 26% of women were infected with HIV following injection drug use.  Non-injection drug 
use was also a risk factor for HIV, likely because of its association with risky sexual behavior.20  
Individuals who struggle with substance abuse issues may avoid seeking treatment because of 
fear of stigma or persecution because of their dependencies.    For HIV-positive pregnant 
women, this is especially true because of fear of criminal prosecution resulting from substance 
abuse during pregnancy.  Substance abuse, like many of the other psychosocial issues discussed, 
can negatively impact a women’s adherence to antiretroviral treatment20.  In addition to 
adherence issues, care providers must consider the possible interactions between street drugs, 
antiretroviral therapies, and therapies for substance abuse.  D ecisions on how  to initiate 
antiretroviral therapy for HIV-positive women struggling with substance abuse must be 
determined on a case-by-case basis20.   
1.4.7 Resource Identification 
The needs of HIV-positive pregnant women extend beyond the clinical setting.  These women 
may need assistance in identifying programs that aid in obtaining low-cost medications, 
knowledgeable HIV case managers or social workers, child care services, HIV support groups, 
HIV counseling services, legal services, and other resources available to the HIV/AIDS 
community.  Understanding what resources are available as health care providers and knowing 
where to refer patients can help manage the various care needs of an HIV-positive patient.  
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Resources for HIV-positive persons vary based on geographical location, urban or rural 
setting, and prevalence of HIV within an area.  Because resources can vary so greatly, national 
services which can aid in resource identification for both providers and patients are described in 
Table 4 and Table 5, respectively. 
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Table 4:  Selected National Resources for Health Care Providers20 
Copyright Permissions Received 
Resource Description Contact information 
AIDS Education 
and Training 
Centers (AETC) 
Regional centers that provide HIV training and education, 
including preceptorships for health care providers; national 
and international centers that provide technical assistance in 
evaluation and specific areas of clinical care, such as 
hepatitis and palliative care; the resource center that provides 
resource materials on a wide range of HIV-related topics and 
links to other centers. 
http://www.aidsetc.org 
 
AIDS info 
Website of the U.S. Public Health Service treatment 
guidelines, continually updated (living documents), clinical 
trials, and drug and vaccine information. 
http://www.aidsinfo.nih.gov 
 
1-800-HIV-0440 
American 
Psychological 
Association Office 
on AIDS 
Organization that provides information, training, and 
technical assistance on HIV/AIDS related topics associated 
with coping, mental health services, prevention, community 
collaboration, and ethics. 
http://www.apa.org/pi/aids 
The Body Pro 
Website with medical treatment information, comprehensive 
care and prevention information, interactive question and 
answers, and access to written information. 
http://www.thebodypro.com 
CDC National 
Prevention 
Information 
Network 
Comprehensive reference, referral, and distribution service 
for information on HIV/AIDS, sexually transmitted diseases, 
and tuberculosis, with information specialists who can assist 
in identifying appropriate resource materials. 
http://www.cdcnpin.org 
 
1-800-458-5231 
HIVdent 
Website with information on the dental manifestations of 
HIV and AIDS including information for persons living with 
HIV/AIDS and their dental care providers. 
http://www.hivdent.org 
 
HRSA HIV/AIDS 
Bureau 
Website of the HIV/AIDS Bureau in the Health Resources 
and Services Administration (HRSA), the federal agency that 
administers the Ryan White CARE Act funding.  
Information and publications supporting care of people with 
HIV, including Special Projects of National Significance 
(SPNS). 
http://www.hab.hrsa.gov 
Kaiser Family 
Foundation 
Organization that informs the U.S. HIV/AIDS policy 
discussion and funds global HIV prevention. 
http://www.kff.org 
National Network 
to End Domestic 
Violence (Hotline) 
Organization that provides domestic violence hotline and 
local resources for women and advocates legally, 
legislatively, and educationally against domestic violence. 
http://www.nnedv.org 
 
1-800-799-SAFE 
Women Children, 
and HIV 
Website with information and provides on prevention of 
perinatal HIV transmission and HIV pregnancy and pediatric 
care, with a global focus, created by the National Pediatric 
Resource Center 
http://www.womenchildrenh
iv.org 
 
The Well Project 
Web Portal for women living with HIV with treatment 
information, discussion groups, organizational tools, slide 
sets, searchable clinical trials listing, and resource 
information. 
http://www.thewellproject.c
om 
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Table 5: Selected National Resources for Patients20    
Copyright Permissions Received                                                                                  
Resource Description Contact Information 
AIDS Alliance for 
Children, Youth, 
and Families 
National association providing advocacy, education, and 
support for children and families affected by HIV/AIDS. 
http://www.aids-alliance.org 
 
1-888-917-AIDS 
 
AIDS info 
Website of the U.S. Public Health Service treatment 
guidelines, continually updated (living documents), clinical 
trials, and drug and vaccine information. 
http://www.aidsinfo.nih.gov 
 
1-800-HIV-0440 
American 
Psychological 
Association Office 
on AIDS 
Organization that provides information, training, and 
technical assistance on HIV/AIDS related topics associated 
with coping, mental health services, prevention, community 
collaboration, and ethics. 
http://www.apa.org/pi/aids 
The Body 
Website with comprehensive HIV information and resources 
for consumers. 
http://www.thebody.com 
CDC National 
Prevention 
Information 
Network 
Comprehensive reference, referral, and distribution service 
for information on HIV/AIDS, sexually transmitted diseases, 
and tuberculosis, with information specialists who can assist 
in identifying appropriate resource materials. 
http://www.cdcnpin.org 
 
1-800-458-5231 
HIVdent 
Website with information on the dental manifestations of 
HIV and AIDS including information for persons living with 
HIV/AIDS and their dental care providers. 
http://www.hivdent.org 
 
HRSA HIV/AIDS 
Bureau 
Website of the HIV/AIDS Bureau in the Health Resources 
and Services Administration (HRSA), the federal agency that 
administers the Ryan White CARE Act funding.  
Information and publications supporting care of people with 
HIV, including Special Projects of National Significance 
(SPNS). 
http://www.hab.hrsa.gov 
National AIDS 
Hotline 
A website and phone hotline to answer consumer questions 
and provide referrals about HIV and AIDS.  Confidential 
inquiries about prevention, risk, testing, treatment, and other 
HIV/AIDS related concerns. 
http://www.ashastd.org/nah 
 
1-800-342-AIDS 
 
National 
Association of 
People with AIDS 
Organization that advocates for and provides information 
and support to people with HIV/AIDS. 
http://www.napwa.org 
 
1-202-898-0414 
National Network 
to End Domestic 
Violence (Hotline) 
Organization that provides national domestic violence 
hotline and local resources for women and advocates legally, 
legislatively, and educationally against domestic violence. 
http://www.nnedv.org 
 
1-800-799-7233 
Project Inform 
Organization that provides consumers with treatment 
information and tools for living with HIV, including 
confidential treatment information by phone and 
ProjectWise, a program focused on HIV/AIDS treatment 
information and advocacy for women. 
http://www.projectinform.or
g 
 
1-800-822-7422 
The Well Project 
Web Portal for women living with HIV with treatment 
information, discussion groups, organizational tools, slide 
sets, searchable clinical trials listing, and resources. 
http://www.thewellproject.c
om 
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2.0  MATERIALS AND METHODS 
2.1 PROGRAM DIRECTOR RECRUITMENT LETTER 
At the time of this investigation, there were 32 genetic counseling graduate programs in the 
United States and Canada.  In order to assess current educational materials in each genetic 
counseling program, it was decided that the program director(s) of each program would be 
invited to participate in our study.  An invitation letter to participate was created and approved 
by the University of Pittsburgh Institutional Review Board, application number PRO10010209.  
A copy of the IRB acceptance letter can be seen in Appendix A. The purpose of this letter was to 
introduce program directors to the project and provide them with a link to access the survey on 
the internet.  This letter was emailed to each program director using the program directors email 
list serve.  A copy of this letter can be seen in Appendix B.   
2.2 SURVEY DESIGN 
A survey was designed for distribution to genetic counseling programs in the United States and 
Canada.  T he survey investigated the availability of educational materials addressing HIV in 
pregnancy as well as the need for additional materials addressing these issues.  Assistance in the 
design and content of this survey was obtained by professionals in both HIV education and 
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genetic counseling.  The content of the survey was approved by the University of Pittsburgh 
Institutional Review Board, application number PRO10010209. A copy of the print version of 
the survey can be seen in appendix C.   
As an introduction to the survey, participants were informed that the purpose of the study 
was to ascertain curriculum content regarding the counseling of HIV-positive pregnant women.  
Participants were asked to answer a series of questions regarding their program’s existing 
educational practices as well as questions about  need for educational materials addressing issues 
related to counseling HIV-positive pregnant women.  T here were no risks associated with the 
completion of the survey and no payment was given when concluded.  Participants were 
reassured that the survey was completely anonymous and results could not be identified in any 
way.   It was stressed that participation in this research project was voluntary and participants 
had the right to not answer any questions they did not feel comfortable with.  A ny questions 
regarding the purpose of the content of the survey were to be targeted to the primary investigator, 
SLC. 
The first part of the survey asked questions regarding the size of the program.  This was 
included to help determine if the size of the program impacts a program’s current offering of 
educational content or need for additional HIV-related content. 
The second part served to assess the current state of existing education on HIV-positive 
pregnant women within genetic counseling programs. Participants were asked if they currently 
provide education regarding HIV-positive pregnant women in their curriculum.  If yes, program 
directors were asked how they offered the material – through lectures, movies, required readings, 
etc.  Space was provided for directors to write in answers if a method used by the program was 
not listed as an option.  The programs that offer education were next asked specific questions 
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about the topics covered within their curricula.  S pecifically, programs were asked if the 
following topics were addressed:   transmission risks during pregnancy and breastfeeding, the 
2006 CDC testing recommendations for pregnant women, current states which include HIV on 
their newborn screening panel, current clinical management recommendations for HIV-positive 
pregnant women, the psychosocial needs of HIV-positive pregnant women, and resource 
identification for HIV-positive pregnant women.  Spaces were provided for directors to write in 
answers if an appropriate option was not available.   
Programs that did not offer testing were asked to describe the reasons why this was.  
Directors were encouraged to choose their top three choices among those suggested (see 
Appendix B), and were also permitted to write in their own reasons if an option was not listed.  
The final part of the survey was a needs assessment to assess if programs would benefit 
from the development of additional materials addressing issues specific to HIV-positive pregnant 
women.  All programs were asked if they would benefit from the creation of additional materials, 
regardless of how they responded regarding their program’s current availability of educational 
material addressing HIV in pregnancy.  If a director answered that they did not think their 
program would benefit from the creation of additional educational materials addressing issues 
pertaining to HIV-positive pregnant women, they were taken to the end of the survey which 
thanked them for their participation. 
If a director answered that they would benefit from the creation of additional educational 
materials, they were then asked which topics they would like to see included.  S pecifically 
program directors were asked if they thought the materials should address transmission risks 
during pregnancy and breastfeeding, the 2006 CDC testing recommendations for pregnant 
women, current states which include HIV on t heir newborn screening panel, current clinical 
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management recommendations for HIV-positive pregnant women, the psychosocial needs of 
HIV-positive pregnant women, and resource identification for HIV-positive pregnant women.  
Space was provided for directors to write in responses if they thought an additional topic should 
be covered that was not listed as an option.   
The final part of the needs assessment asked what types of products directors would most 
benefit from.  P articipants were asked to pick their top three choices.  C hoices included 
production of webinars, PowerPoint presentations on relevant topics, a pocket guide for genetic 
counselors, clinical case examples, and packets or relevant peer-reviewed articles as well as 
other types of potential educational materials.  To see the complete listing, please see Appendix 
B.   
Following the completion of the needs assessment, program directors were taken to the 
end of the survey, which thanked them for their participation. 
2.3 SURVEY DISTRIBUTION/RESULTS COLLECTION 
In order to efficiently distribute and collect the results for the survey, the survey was made 
available electronically through SurveyMonkey, www.surveymonkey.com.   
The survey found in Appendix B was transferred into an online format using 
SurveyMonkey.  T he only changes made to the survey in Appendix B was the re-ordering of 
some questions due to the incorporation of skip logic.  Skip logic allows for better organization 
and helps streamline the process for those taking the survey.  Instead of following directions such 
as, “If you answered yes, skip ahead to question 6”, skip logic sorts answers accordingly and 
automatically directs participants to the next appropriate question.   
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To direct participants to the survey, a link was created that directed directors to the start 
of the survey.  Th is link was distributed in the email sent to program directors. A list of the 
program directors can be seen in Table 6. 
 
Table 6:  Genetic Counseling Programs Contacted for Participation 
Program Name Location 
University of Alabama at Birmingham Birmingham, AL 
University of Arkansas Medical Center Little Rock, AR 
University of California, Irvine Orange, CA 
California State University – Stanislaus Turlock, CA 
Stanford University Stanford, CA 
University of Colorado, Denver Denver, CO 
Howard University Washington, DC 
Northwestern University Medical School Chicago, IL 
Indiana University Medical Center Indianapolis, IN 
Johns Hopkins University/National Human Genome 
Research Institute 
Baltimore, MD 
University of Maryland School of Medicine Baltimore, MD 
Boston University School of Medicine Boston, MA 
Brandeis University Waltham, MA 
University of Michigan Ann Arbor, MI 
Wayne State University Detroit, MI 
University of Minnesota Minneapolis, MN 
Mt. Sinai School of Medicine New York, NY 
Sarah Lawrence University Bronxville, NY 
University of North Carolina at Greensboro Greensboro, NC 
Case Western Reserve University Cleveland, OH 
University of Cincinnati, College of Allied Health 
Sciences 
Cincinnati, OH 
University of Oklahoma Health Sciences Center Oklahoma City, OK 
Arcadia University Glenside, PA 
University of Pittsburgh Pittsburgh, PA 
University of South Carolina Columbia, SC 
University of Texas Graduate School of Biomedical 
Sciences at Houston 
Houston, TX 
University of Utah Salt Lake City, UT 
University of Wisconsin-Madison Madison, WI 
Medical College of Virginia/Virginia Commonwealth 
University 
Richmond, VA 
University of British Columbia Vancouver, British Columbia, Canada 
University of Toronto Toronto, Ontario, Canada 
McGill University Montreal, Quebec Canada 
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The survey was initially sent on July 15, 2010.  A reminder email was sent on August 1, 
2010 and the survey was closed on September 1, 2010.   
Responses were collected and analyzed using features found on SurveyMonkey.  
SurveyMonkey allows administrators to download responses, sort answers by certain 
characteristics, and create figures.  SurveyMonkey is compatible with Microsoft Excel, and 
results were downloaded directly into this program for easier access and analysis.  
2.4 DATA ANALYSIS 
For analysis, responses were tabulated and compared.  T he majority of the responses 
were “yes/no” questions that did not require any statistical analysis. Tables and figures were 
made summarizing tabulated responses and percentages for each question.  Some responses were 
stratified by size of program, specifically questions asking about availability of educational 
material and need for additional material.  To determine if differences existed between size of 
program and availability of education or need for educational materials, Jonckheere-Terpstra (J-
T) tests for ordered categorical data were completed. The J-T test determines if there is a 
statistical difference between observed values which are presumed to have ordered differences.   
Fisher’s exact test was used to determine if there was a difference between the availability of 
educational materials in a program and the need for additional materials.  This test is appropriate 
because of the small size of some observed values.  SAS Version 9.2 was used for all statistical 
analysis.     
To determine the types of educational materials that should be produced, it was decided 
that the top three responses requested by program directors would be areas of focus.   Topics for 
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inclusion in these materials would depend on t he responses provided by genetic counseling 
programs who thought they would benefit from additional educational materials. 
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3.0  RESULTS 
3.1 SURVEY RESULTS 
Of 32 programs surveyed, 26 chose to respond.   This corresponds to a response rate of 81.26%.  
Programs were asked to indicate how many students were in each year of their program.  The 
results can be seen in Figure 6. 
   
 
Figure 6:  Number of Students Per Year in Surveyed Programs 
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Of the programs surveyed, 46.2% had 6-10 students in each year of their program, 26.9% 
had 11-15, 19.2% had 0-5, and 7.7% had >15.   
Programs were next asked if they offer any education regarding HIV in pregnancy within 
their curricula.  Education regarding HIV-positive pregnant women was reported as part of 
existing curricula by 65.4% of the respondents.  
To determine if there were differences between program size and availability of 
educational materials addressing HIV in pregnancy, responses from this question were broken 
down by program size.  This can be seen in Table 7.  
 
Table 7:  Size of Program vs. Availability of Educational Materials 
Size of Program 0-5 6-10 11-15 >15 
Offer Material 3 (60%) 7(58.3%) 5 (71.4%) 2(100%) 
Do Not Offer 
Material 
2 (40%) 5 (41.7%) 2 (28.6%) 
0 (0%) 
 
To determine if the observed differences were statistically significant, the J-T test was 
performed.  This test generated a one-sided p-value of .3750, which indicates that the variances 
observed did not significantly differ for programs of different sizes.   
 
3.1.1 Programs that Offered Educational Content 
Of the 17 pr ograms that provided education regarding HIV and pregnancy, 16 a nswered the 
following questions regarding the types of education provided.   
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Participants were asked how the existing content was structured within their curricula.  
Participants were asked to choose all options that applied.  The results of this question can be 
seen in Figure 7.    
 
 
Figure 7:  Type of Educational Materials Addressing HIV and Pregnancy Utilized by Genetic Counseling 
Programs 
 
The most common type of educational material used by programs is to address HIV in 
pregnancy within another lecture, which accounted for 56.3%.  The next most common type of 
education was an entire lecture dedicated to HIV in pregnancy, which was represented 31.3% of 
the responses collected.  Required readings on HIV and pregnancy represented 12.5% of existing 
curricula and more than one lecture on HIV and pregnancy corresponded to another 6.3%.  In 
addition, four separate responses were included in the ‘Other’ option.  These responses included 
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“a very brief mention of HIV in prenatal genetics class”, “more info on HIV and pregnancy is 
covered in epidemiology course”, “component of teratogen module”, and “we view the film And 
then the Band Played On as an introduction to the HIV epidemic”.   N o programs reported 
offering education in the form of required web-based tutorials on HIV in pregnancy, optional 
web-based tutorials on HIV in pregnancy, required documentary or film addressing HIV in 
pregnancy, or optional documentary or film addressing HIV in pregnancy.   
The next series of questions asked specifics about the exact topics addressed by genetic 
counseling programs. 
3.1.1.1  HIV Transmission Risks 
Of the programs who provided education, 93.8% included content addressing the risk of 
perinatal transmission.  The programs that answered yes were asked more specifically which 
topics were covered regarding perinatal HIV transmission risks.  The results of this question are 
seen in Figure 8.   
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Figure 8:  Specific Topics Included by Programs who Provide Education Addressing Perinatal Transmission 
Risks of HIV 
 
The three most commonly discussed topics were transmission risks during labor and delivery, 
transmission risks in utero, and transmission risks during early invasive diagnostic procedures.  
These topics were covered by 92.3%, 76.9%, and 76.9% of programs respectively.   The risk of 
HIV crossing the placenta was addressed by 61.5% of programs. The remaining responses were 
less commonly included in existing curricula; 46.2% discussed the current recommended 
methods of delivery for HIV-positive women, 30.8% discussed the effects of HIV on bi rth 
weight, and 7.7% indicated that they covered ‘Other’ topics.  The ‘Other’ response referred to 
“retroviral recommendations to lower viral count”.   
Program directors were next asked if perinatal transmission risks due to breastfeeding 
were included within course materials.   This topic was included by 64.3% of programs.  
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3.1.1.2  CDC Testing Recommendations 
Of the 16 programs that provided educational content addressing HIV and pregnancy, 14 
chose to answer the question regarding inclusion of the 2006 CDC testing recommendations.  
CDC HIV testing recommendations were discussed by 57.1% of programs, while 42.9% did not 
provide education on this topic.  
3.1.1.3 Newborn Screening 
Of the 16 programs that provided educational content addressing HIV and pregnancy, 14 
chose to answer the question regarding newborn screening guidelines for HIV.  N ewborn 
screening for HIV was included in 28.6% of the program’s existing curricula.  The majority of 
programs, 71.4%, did not include this topic within their discussion of HIV and pregnancy.    
3.1.1.4  Clinical Management 
Of the 16 programs that provided educational content addressing HIV and pregnancy, 14 
chose to answer the question regarding guidelines and recommendations for the clinical 
management of an HIV-positive pregnant woman.  Of the respondents, 28.6% indicated that they 
covered this issue, while 71.4% did not.   
Programs that answered “yes” were asked more specifically which topics they covered 
regarding clinical management.   The results of this question can be seen in Figure 9.  
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Figure 9:  Specific Topics Included by Programs who Provide Education Addressing Clinical Management of 
HIV-Positive Pregnant Women 
 
All programs included the discussion of the teratogenic risks of HIV antiretroviral 
medications within their curricula. The next most commonly discussed topic regarding clinical 
management was the recommended antiretroviral medications for the treatment and management 
of HIV-positive pregnant women, which was addressed by 75% of programs.  In addition, 75% 
of programs also addressed long-term risks posed to the infant following in-utero exposure to 
antiretroviral medications.  O f the programs who responded, 50% reported that they address 
recommendations for antiretroviral medications during labor and delivery, the interactions 
between antiretroviral medications and other medications, and clinical/biological monitoring for 
women during pregnancy.  Another 25% of programs discussed the need for recurrent testing 
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during the course of pregnancy and at labor and delivery.  Finally, 25% of those who answered 
chose ‘other’ which corresponded to ‘done within the context of a series of teratology lectures’. 
3.1.1.5 Psychosocial Needs of HIV-positive Pregnant Women 
Of the 16 programs that provided educational content addressing HIV and pregnancy, 14 
chose to answer the question regarding the psychosocial needs of HIV-positive pregnant women.  
Of the programs surveyed, 21.4% included instruction regarding these needs, while 78.6% did 
not.   
Programs that answered yes were asked more specifically which topics they covered 
regarding psychosocial issues. The results can be seen in Figure 10. 
 
 
Figure 10:  Specific Topics Included by Programs who Provide Education Addressing Psychosocial Issues for 
HIV-Positive Pregnant Women 
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All programs provided a discussion on c ultural competency, social support issues, and 
stigma associated with the diagnosis of HIV.  Substance abuse/use and sexual violence/abuse 
were addressed within the discussion of psychosocial needs of HIV-positive pregnant women by 
66.7% of programs.  Finally, 33% of programs responded that they cover psychiatric sequalae of 
HIV, depression/suicide risks, anxiety, and multiple diagnoses.  One final respondent answered 
‘other’, which corresponded to “done within the context of addressing these issues in a variety of 
settings”. 
 
3.1.1.6  Resource Identification 
Of the 16 programs that provided educational content addressing HIV and pregnancy, 14 
chose to answer the question regarding resource identification for HIV-positive pregnant women.  
Of the programs surveyed, 42.9% provided education about resource identification, while 57.1% 
did not.    
Programs that answered yes were asked more specifically which topics they covered 
regarding resource identification. The results can be seen in Figure 11.  
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Figure 11:  Specific Topics Included by Programs who Provide Education Addressing Resource Identification 
for HIV-Positive Pregnant Women 
 
All of the programs surveyed provide education on r esource identification discussed HIV 
counseling services and 66.7% discussed HIV support groups and treatment clinics in their areas.  
Of programs that responded, 50% provided information on HIV/AIDS drug assistance programs 
and social workers/case workers who specialize in providing care to HIV-positive individuals.  
An additional 16.7% indicated that they address clergy/spiritual support or “Other” resource 
identification topics, which corresponded to “Most of this material is covered in the prenatal 
clinical settings”.  Finally, no pr ograms indicated that they discuss child care services, legal 
services, needle exchange programs/substance abuse rehabilitation programs, and subsidized 
housing for HIV-positive persons. 
 70 
3.1.2 Programs that did not Offer Educational Content 
Of the 26 r espondents of the survey, 9 di d not offer any education within their curricula for 
genetic counseling students addressing HIV in pregnancy.  These respondents were then asked to 
identify the top three reasons why education was not provided.  The results can be seen in Figure 
12.    
 
Figure 12:  Reasons Programs do not Offer Educational Content Addressing HIV and Pregnancy 
 
The top three reasons for not including information regarding HIV and pregnancy within 
their curricula were a lack of time/space to incorporate the topic, the need for specific content is 
not warranted because the patient population is not large enough, and counseling about HIV is 
not the role of genetic counselors.  T hese options were chosen by 70%, 50%, and 40% of 
programs surveyed, respectively.  In addition, 30% of programs reported that a lack of available 
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educational materials was one of the top three reasons they did not offer discussion of HIV and 
pregnancy within their curricula.   T he remaining 10% of respondents indicated that the reason 
education was not included within existing curricula was due to insufficient faculty knowledge 
regarding HIV/AIDS during pregnancy, lack of knowledgeable faculty, students have not 
requested the topic to be covered, and training on HIV-positive pregnant women is not needed.  
Finally, 10% chose ‘Other’ as one of their top three reasons, which corresponded to “Not 
covered in class, but hope that students gain some exposure/experience during clinical rotations”.  
No programs indicated that the lack of education was due to a conflict with program goals. 
3.1.3 Needs Assessment 
Following the completion of the portion of the survey that dealt with existing curricula, programs 
were asked to complete a needs assessment.  The needs assessment focused on determining if 
programs would benefit from the development of additional educational materials, topics desired 
for inclusion, and types of materials desired for development.   
3.1.3.1 Utility of Additional Educational Materials 
The 16 programs that offered educational content on HIV and pregnancy were asked if 
they would benefit from the creation of additional educational materials.   Of the 16 programs 
who offered educational material, 14 chose to respond to this question.  The majority of 
programs, 64.3%, indicated that they would benefit from the development of additional 
educational materials addressing issues regarding HIV/AIDs and pregnancy, while 35.7% 
answered that they would not.  Results were then stratified by size of program to see if any 
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trends existed for size of program and need for existing educational materials.  The results can be 
seen in Table 8.     
 
Table 8:  Programs That Currently Offer Education:  Need for Additional Materials by Size of Program  
Size of Program 0-5 6-10 11-15 >15 
Would Benefit from 
Additional Materials 
1 2 4 2 
Would not Benefit From 
Additional Materials 
1 4 0 0 
 
To determine of the differences observed were statistically significant, the J-T test was 
performed.  The results of this test resulted in a one-sided p-value of .25, which indicates that the 
observed differences are not statistically significant. 
The 9 programs that did not offer any education within their curricula regarding HIV and 
pregnancy were also asked if they would benefit from the development of additional materials.  
88.9% of programs said they would benefit from additional materials addressing issues regarding 
HIV/AIDS and pregnancy and 11.1% indicated that they would not.   Results were then stratified 
by size of program to see if any trends existed for size of program and need for existing 
educational materials.  The results can be seen in Table 9.    
 
Table 9:  Programs That Do Not Currently Offer Education:  Need for Additional Materials by Size of 
Program  
Size of Program 0-5 6-10 11-15 >15 
Would Benefit from 
Additional Materials 
1 5 1 0 
Would not Benefit From 
Additional Materials 
1 0 0 0 
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To determine of the differences observed were statistically significant, the J-T test was 
performed.  The results of this test resulted in a one-sided p-value of .25, which indicates that the 
observed differences are not statistically significant. 
Comparing the numbers of programs that thought additional materials would be 
beneficial to those who would not regardless of program size, it was seen that programs who 
didn’t currently offer education were more likely to ask for educational materials.   The results 
can be seen in Table 10. 
 
Table 10:  Need for Additional Educational Materials vs. Current Availability of Educational Material 
  Offered Education Did not Offer Education 
Would Benefit from Additional Materials 
9 8 
Would not Benefit From Additional 
Materials 5 1 
 
To determine if the observed differences were statistically significant, Fisher’s Exact Test 
was performed.  This test yielded a p-value of .340, which indicates the observed differences are 
not significantly different between programs who offered education and those that did not. 
3.1.3.2 Topics to be Included in Educational Material 
In order to assess which subjects should be included, the 17 programs that would benefit 
from additional materials were polled on what topics they would like to see covered. 
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HIV Transmission Risks 
Of the programs who felt that their program would benefit from additional materials,  
94.1% of programs thought that the materials should address perinatal transmission risks.   
Programs that wanted information on perinatal transmission risks were polled regarding which 
specific topics they would like to see addressed.  The results can be seen in Figure 13. 
 
 
Figure 13:  Specific Topics Regarding HIV Perinatal Transmission Risks Requested for Inclusion in 
Developed Educational Materials 
 
Information addressing transmission risks in utero and during labor and delivery was 
requested for inclusion in the developed materials by 93.8% of the programs surveyed.   In 
addition, 87.5% of those polled indicated that HIV crossing the placenta, the impact of HIV on 
birth weight infants, and the transmission risks during early invasive diagnostic procedures 
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incorporated.  Current recommended methods of delivery were requested by 75% of respondents.  
Finally 25% of those who answered indicated they would like “Other” topics covered.  These 
topics included “newborn screening issues”, “similarities between HIV counseling and genetic 
counseling”, “psychosocial needs of affected women”, and “how to facilitate discussion 
regarding HIV with partner(s)”.    
Program directors were asked if the materials should address transmission risks that occur 
as a result of breastfeeding breastfeeding.  Of the programs that responded, 76.5% indicated that 
they would like to see this topic covered, while 23.5% said they would not. 
CDC Testing Recommendations 
Programs that wanted additional materials were asked if developed materials should 
include information regarding the 2006 CDC Recommendations for HIV screening of pregnant 
women.  Overall, 88.2% thought this topic would be worthwhile to include in materials, while 
11.8% said they did not think it was needed. 
Newborn Screening 
Programs that wanted additional materials were asked if developed materials should 
include information on the subject of newborn screening for HIV.   Of the programs that 
responded, 88.2% of programs surveyed indicated this topic should be included in developed 
materials and 11.8%  did not. 
Clinical Management 
Programs that wanted additional materials were asked if developed materials should 
include information on current clinical management guidelines for HIV-positive pregnant 
women.  This topic was requested by 70.6% of programs.  Programs that wanted this subject 
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included were asked about specific topics to be addressed in developed materials.  The results 
can be seen in Figure 14.     
 
 
Figure 14:  Specific Topics Regarding Clinical Management Requested for Inclusion in Developed 
Educational Materials 
 
All of the programs who responded requested that teratogenic effects of HIV 
antiretroviral medications be discussed and 91.7% thought that the recommendations for the use 
of HIV medications during labor and delivery should be addressed.  The long-term effects of 
HIV medications were requested to be included by 83.3% of programs.  Current recommended 
HIV antiretroviral medications, clinical biological monitoring during pregnancy, and interactions 
between HIV medications and other medications were requested for inclusion by 66.7% of the 
programs.  In addition, 58.3% thought that the need for recurrent testing following the entry of 
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care by an obstetrician and at labor and delivery should be included in potential materials.   
Finally, 8.3% of those polled chose “other”, which corresponded to “support needs of patients”.   
Psychosocial Needs of HIV-positive Pregnant Women 
Programs that wanted additional materials were asked if developed materials should 
address the psychosocial needs of HIV-positive pregnant women.  All of the programs surveyed 
thought this was a topic that should be included.  T he programs were next asked which 
psychosocial needs should be addressed specifically.  The results can be seen in Figure 15.     
 
 
Figure 15:  Specific Topics Regarding Psychosocial Issues Requested for Inclusion in Developed Educational 
Materials 
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Stigma associated with an HIV diagnosis was requested for inclusion in developed 
materials by 94.1% of programs.  The next most commonly requested topic was cultural 
competency, at 88.2%.   In addition, 82.4% of programs thought that substance abuse and 
anxiety associated with a diagnosis of HIV should be included.  Depression and suicide risk were 
the next most commonly requested topic, at 76.5%.  Of the programs that responded, 70.6% of 
respondents thought that social support issues and sexual/domestic violence should be addressed.  
The least commonly requested topics were psychiatric sequalae of HIV, at 58.8%, and multiple 
diagnoses, at 52.9%.  No programs chose ‘Other’ as a response. 
Resource Identification 
Programs that wanted additional materials were asked if developed materials should 
include information on r esource identification.  Of those surveyed, 58.8% thought that the 
materials should address this topic, while 41.2% did not.  The participants who wanted additional 
materials addressing resource identification were then asked which specific topics should be 
included.  The results can be seen in Figure 16.   
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Figure 16:  Specific Topics Regarding Resource Identification Requested for Inclusion in Developed 
Educational Materials 
 
Of the programs that responded, 90% thought that the materials should address 
identification of available case managers/social workers, HIV counseling services, HIV support 
groups, and HIV treatment clinics.  AIDS drug assistance programs were requested by 80% of 
programs.  In addition, 50% of programs asked that child care services, clergy/spiritual support, 
legal services, and subsidized housing for HIV-positive persons be discussed.  Finally, 40% of 
programs thought that needle exchange programs and substance abuse treatment programs 
should be included in the developed materials.   
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Other Topics 
In order to determine if program directors desired materials addressing topics not already 
mentioned, respondents were asked if there were any additional topics they would like to see 
covered.  Of those polled, 18.8% indicated they would like to see other topics included.  When 
prompted to describe these additional topics, the following responses were received:  “Important 
to continue to develop strategies to identify women who may be at risk of abuse or domestic 
violence although unstated”, “ethical issues”, and “facilitating the discussion of HIV with sex 
partner(s)”.   
3.1.4 Types of Materials Requested 
Following the completion of the needs assessment, programs who requested additional materials 
were asked to choose types of materials which would most benefit students.   Programs were 
asked to choose their top three choices and the results can be seen in Figure 17.     
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Figure 17:  Types of Materials Addressing HIV and Pregnancy Program Directors would Most Benefit From  
 
The three most requested educational materials were clinical case examples which can 
illustrate key points of counseling HIV-positive women in a genetic counseling practice; a CD-
ROM of PowerPoint lectures addressing HIV basics, perinatal transmission risks, current CDC 
recommendations for HIV screening during pregnancy, and the implications for genetic 
counselors of counseling HIV-positive pregnant women; and a series of online webcasts that 
could be viewed at any time by students at 70.6%, 64.7%, and 47.1%, respectively.   In addition, 
29.4% of programs requested role playing scenarios that could be used in class by students to 
practice skills learned and a list of websites that would contain valuable resources for faculty and 
students.  Less commonly requested materials were an HIV pocket guide, requested by  17.6% of 
programs, and packets of relevant peer reviewed articles or lists of current documentaries, books, 
popular movies, etc. that illustrate the needs of an HIV-positive patient, requested by 11.8% of 
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programs.  Quizzes on relevant topics in HIV education for genetic counselors were chosen by 
5.9% of respondents as being one of the top three most useful educational materials that could be 
developed.  No respondents indicated that a series of audio lectures or ‘Other’ materials would 
be in their top three choices for developed educational materials. 
3.2 DEVELOPMENT OF MATERIALS 
As discussed, the three most common educational materials requested by program directors were 
webinars, clinical case examples, and a CD-ROM containing PowerPoint presentations and other 
resources addressing issues related to HIV and pregnancy.  These materials were developed for 
distribution to genetic counseling programs. 
3.2.1 Webinars 
Program directors indicated that webinars would be a desirable educational material produced to 
address issues pertaining to the counseling of HIV-positive pregnant women, so it was decided 
that two webinars would be developed.  T he Pennsylvania/MidAtlantic AIDS Education and 
Training Center (PA/MAAETC) is a non-profit organization funded by the Health Resources and 
Services Administration (HRSA) HIV/AIDS Bureau that is located in the University Of 
Pittsburgh Graduate School of Public Health.  The PA/MAAETC serves to develop educational 
programming for clinicians addressing the needs of HIV-positive patients.  T he clinicians 
traditionally targeted by the PA/MAAETC are physicians, physician assistants, nurses, 
advanced-practice nurses, dentists, and social workers.   T he programs developed by the AETC 
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cover all areas of HIV epidemiology, risk assessment, prevention, and management.   The 
PA/MAAETC is dedicated to bringing HIV education to all types of health care professionals, 
and graciously agreed to coordinate, fund, advertise, and distribute the webinars for this project.  
Funding for the webinars was made possible by a grant from HRSA, HIV/AIDS Bureau, 
Division of Training and Technical Assistance, Grant No. HFAHA00060. 
The webinars were advertised by the PA/MAAETC through e-mail to genetic counselors 
as well as other healthcare professionals targeted by the PA/MAAETC.  Thirty days following 
the completion of the live webinars, the presentations were archived on the PA/MAAETC’s 
website to be viewed at participant’s convenience, free of charge.  The archived webinars can be 
found at www.pamaaetc.org. 
3.2.1.1 The HIV-positive Pregnant Woman:  T ransmission Risks, Management, and 
Recommendations 
The first webinar developed served to address transmission risks, management, and 
recommendations for the care of HIV-positive pregnant women.  This webinar was presented by 
Katherine Bunge, M.D., an associate professor of obstetrics and gynecologist at Magee Womens 
Hospital in Pittsburgh, PA.  Dr. Bunge is an expert in providing care to HIV-positive pregnant 
women and is a frequent speaker for the PA/MAAETC on this topic. 
The webinar was designed to last 60 minutes and involved a lecture accompanied by a 
PowerPoint presentation.  Participants were able to ask questions following the conclusion of the 
presentation.  Development of the webinar focused on addressing issues identified by program 
directors for inclusion in developed educational materials.  T opics covered included perinatal 
transmission risks, current recommendations for delivery, the effect of maternal/fetal HIV on 
fetal birth weight, transmission risks during invasive procedures such as amniocentesis and 
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chorionic villus sampling, and basic clinical management guidelines for HIV-positive pregnant 
women.   In addition, the webinar addressed some epidemiological data on HIV-positive 
pregnant women, such as pregnancy trends and the change in the number of HIV-positive infants 
born since the beginning of the epidemic. Objectives for participants completing the webinar 
were to understand the transmission risks for infants born to HIV-positive pregnant women, 
describe management recommendations for HIV-positive pregnant women, and gain insight into 
the effects of HIV on the fetus and the newborn.   
 A flyer developed to advertise for this program can be seen in Figure 18.   
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Figure 18:  Flyer Advertising “The HIV-Positive Pregnant Woman:  Transmission Risks, 
Recommendations, and Management” 
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3.2.1.2 Women and HIV:  Approach to Comprehensive Care and Psychosocial issues 
The second webinar developed served to address approaches to care and psychosocial 
issues specific to HIV-positive women.  The webinar was presented by Linda Frank, PhD, MSN, 
ACRN, FAAN and Patricia Lincoln, BSN, RN, ACRN.  Dr. Frank is an Associate Professor in 
the Department of Infectious Diseases and Microbiology at the Graduate School of Public Health 
at the University of Pittsburgh in Pittsburgh, PA.  In addition, Dr. Frank serves as the Principal 
Investigator and Executive Director of the PA/MAAETC.  Ms. Lincoln is the Local Performance 
Site Director for the Delaware/Christiana Care Health Services local site of the PA/MAAETC.  
Dr. Frank and Ms. Lincoln are experts in the field of HIV education and patient management.  
The webinar was designed to last 60 minutes and involved a lecture accompanied by a 
PowerPoint presentation.  Participants were able to ask questions following the conclusion of the 
presentation.  Development of the webinar focused on addressing issues identified by program 
directors for inclusion in developed educational materials.  Topics covered included cultural 
competency and how it relates to HIV, social support issues, substance use/abuse, sexual and 
domestic violence, stigma associated with an HIV diagnosis, depression and suicide risks, mental 
health concerns, approaches to care, and resource identification for HIV positive women.   
Objectives for participants completing the webinar were to recognize the impact of stigma on 
HIV-positive women, correlate the risk of anxiety/depression with an HIV diagnosis, explore the 
importance of social support networks for HIV-positive women, summarize skills health 
professionals can use to assist in coping with an HIV diagnosis, describe the approaches to care 
for HIV-positive women, and discuss barriers to treatment for HIV-positive women. 
A flyer developed to advertise for this program can be seen in Figure 19.   
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Figure 19:   Flyer advertising “Women & HIV:  Approach to Comprehensive Care and Psychosocial Issues” 
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3.2.2 Clinical case studies 
Program directors indicated that clinical case examples to illustrate issues that could arise when 
counseling an HIV-positive pregnant woman would also be valuable.  To meet this need, six case 
examples were drafted.  The case examples were developed in the context of prenatal genetic 
counseling sessions for referral reasons which are familiar to genetic counseling students.  B y 
incorporating the issue of an HIV diagnosis into the examples, students were prompted to discuss 
some key points of counseling, risk assessment, and management for patients with HIV who may 
be receiving genetic counseling.  A diverse patient population was used to help students think of 
different issues that could result from counseling women of different age groups and ethnic 
backgrounds.  
Case examples were reviewed and revised by genetic counselors as well as HIV 
professionals to make sure that issues for both fields were relevantly incorporated.  The clinical 
case examples will be included for distribution on the CD-ROM that was also developed for 
genetic counseling programs. 
The clinical case examples developed can be seen in Table 11. 
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Table 11:  Clinical Case Examples Designed For Genetic Counseling Programs 
Clinical Case Examples 
 
V.C. is an 18 y/o African-American woman referred to genetic counseling because of a personal 
history of diabetes and to have first trimester screening done.  While reviewing her records, you see 
that her prenatal labs were positive for HIV and she is currently taking Efavirenz as part of her 
HAART regimen.  She is currently 12 weeks pregnant.  What risks should you discuss with V.C. 
during the counseling session in addition to her diabetes-associated risks?  What tests should she be 
offered to help clarify these risks?   
 
 
D.S. is a 24 y/o Ashkenazi-Jewish woman who is referred to genetic counseling for carrier screening.  
During the session, D.S. informs you that she recently found out she was HIV-positive and is 
considering termination because “she knows that her baby will be infected with HIV.”  What risks 
would you provide her for transmission during pregnancy?  What intervention methods would you 
discuss with her to lower these risks?   
 
 
N.E. is a 31 y/o Caucasian woman who is referred to genetic counseling following an elevated quad 
screen.  Her risk for Down syndrome came back 1:40.  While reviewing her records, you see that she 
is HIV positive and is currently receiving HAART therapy.   Would this change her quad screen 
result?  How would you explain the findings to the patient?  What tests would you recommend?   
 
 
S.C. is a 41 y/o Asian female who is referred to counseling for advanced maternal age.  She is 11 
weeks 4 days pregnant and wants to have a chorionic villus sampling.  While taking her history, S.C. 
tells you that she has HIV.  How would you counsel her regarding the risk of perinatal transmission 
associated with CVS? 
 
 
M.D. is a 27 y/o female of Hispanic ethnicity who is referred to counseling because of a personal 
history of neurofibromatosis.  During the session, she becomes emotional and discloses she was just 
told she was HIV-positive.  She is afraid to tell her family because she is afraid of their reactions.  
How would you counsel her?  What resources could you provide her to help in the disclosure process 
as well as coping with a new diagnosis?   
 
 
R.W. is a 32 y/o Caucasian woman who just delivered a baby who tested positive for HIV and cystic 
fibrosis on newborn screening panels.  She is referred to you to discuss the results of these tests.  
What do the baby’s test results imply for R.W.?  Should she breastfeed her infant?   
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3.2.3 CD-ROM of PowerPoint Presentations and Additional Relevant Resources 
The third most common resource requested by program directors was a CD-ROM of PowerPoint 
presentations and other materials addressing issues specific to HIV during pregnancy.   T he 
PowerPoint presentations from the webinars, clinical case examples, and additional resources 
that would be beneficial to providing education to genetic counseling students were included on 
this CD-ROM.  The additional resources included are listed in Table 12.   
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Table 12:  Resources Included in the CD-ROM Developed for Genetic Counseling Programs 
Title Source 
2006 Revised Recommendations for HIV Testing of Adults, 
Adolescents, and Pregnant Women in Health-Care Settings. 
Centers for Disease Control and 
Prevention 
Panel on Treatment of HIV-infected Pregnant Women and 
Prevention of Perinatal Transmission Recommendations for Use of 
Antiretroviral Drugs in Pregnant HIV-1-Infecteed Women for 
Maternal Health and Interventions to Reduce Perinatal HIV 
Transmission in the United States 
AIDSinfo:  A Service of the U.S. 
Department of Health and Human 
Resources 
Supplement: Safety and Toxicity of Individual Antiretroviral 
Agents in Pregnancy 
AIDSinfo:  A Service of the U.S. 
Department of Health and Human 
Resources 
A Guide to the Clinical Care of Women with HIV, 2005 edition. 
U.S. Department of Health and Human 
Services, Health Resources and 
Services Administration, HIV/AIDS 
Bureau 
The Invisible Epidemic:  Women with HIV in the United States 
• Women, HIV, and HAART:  The Basics 
o Provider Counseling Guide 
o Patient Booklet 
• Women, HAART, and Pregnancy 
o Provider Counseling Guide 
o Patient Booklet 
• Women and Adhering to HAART 
o Provider Counseling Guide 
o Patient Booklet 
• Women, HAART, and Side Effects 
o Patient Booklet 
• Women, HAART, and Healthy Living 
o Provider Counseling Guide 
o Patient Booklet 
• Resource Guide 
Annenberg Center for Health Sciences, 
Association of Nurses in AIDS Care, 
Postgraduate Institute of Medicine, 
Health Matters Continuing Medical 
Education, and Tibotec. 
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4.0  DISCUSSION 
Genetic counselors will rarely be faced with a woman who is HIV-positive that is referred only 
because of her HIV status.  It is more likely that an HIV-positive woman will be referred to 
genetic counseling because of additional concerns regarding her pregnancy in addition to her 
HIV status.  If an HIV-positive pregnant woman is being referred to genetic counseling, it is  
likely that she is receiving prenatal care, and that her obstetrician/gynecologist is helping manage 
her care regarding her HIV diagnoses.  Genetic counselors should not be expected to direct care 
regarding a woman’s HIV status, but should be familiar with issues that can have an impact on 
the pregnancy and are relevant to genetic counseling sessions.  Issues including transmission 
risks, teratogenic impact of HIV medications, psychosocial issues, and newborn screening 
policies are all subjects which are important to genetic counselors for a variety of conditions, not 
just HIV.  Based on the experiences of this author, it was hypothesized that genetic counselors do 
not offer adequate education regarding HIV in pregnancy.  This is the first study conducted 
which investigates the inclusion of educational materials addressing HIV in pregnancy within the 
curricula of genetic counseling programs in the United States and Canada.  The purpose of this 
study was to investigate the current availability of education addressing HIV in pregnancy and 
the needs of HIV-positive pregnant woman in genetic counseling programs in the United States 
and Canada.  T his study also served to conduct a needs assessment for the development of 
additional educational materials that would benefit genetic counseling programs.   
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The majority of genetic counseling programs in the United States offer some education 
on HIV and pregnancy.  Of the programs surveyed, 65.4% of currently address HIV in 
pregnancy, and the availability of education varied based on program size.  As seen in Table 7, 
as program size increased, the availability of education addressing HIV in pregnancy also 
increased.  It was hypothesized that this could be explained because larger programs have access 
to more resources as compared to smaller programs.  To determine if the differences observed 
were statistically significant, the Jonckheere-Terpstra (J-T) was used to determine if the trends 
observed were significantly different.  The results of the J-T test indicated that there was not a 
statistically significant difference between availability of HIV education and size of program.  
This could be because the sample size was not large enough to detect differences.  This 
limitation in sample size is difficult to overcome because of the limited numbers of genetic 
counseling programs in the United States and Canada. 
The mode of delivery of education also varied between programs.  The majority of 
programs, 56.3%, addressed HIV in pregnancy within another lecture and 31.3% of programs 
dedicated an entire lecture to HIV.  The results of this question are not surprising because the 
majority of programs only address a few topics regarding HIV in pregnancy.  A summary of the 
availability of different subjects that programs include within their curricula can be seen in 
Figure 20. 
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Figure 20:  Topics Addressed by Genetic Counseling Programs Regarding HIV in Pregnancy 
 
The majority of genetic counseling programs who responded, 93.8%, address perinatal 
transmission risks.  Thinking about the components of a prenatal genetic counseling session, this 
finding is not surprising.  Perinatal transmission risks are an important topic for genetic 
counseling students to understand so they can accurately present these risks to their patients.  
Other topics regarding HIV in pregnancy were not as frequently discussed in genetic counseling 
programs.  T his could be because a lack of familiarity with some of these topics, such as the 
2006 CDC testing recommendations, clinical management, and resource identification for HIV-
positive pregnant women.  More surprising is the finding that the majority of programs that offer 
educational content regarding HIV in pregnancy do not  cover the psychosocial needs of HIV-
positive pregnant women or newborn screening programs that include HIV.  E ducation 
addressing the psychosocial issues of various patient populations is an important component of 
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genetic counseling training programs.  A s discussed, women with HIV have a unique set of 
psychosocial considerations which differ from women without HIV.  Genetic counselors may 
benefit from education addressing these issues so they are familiar with the specific needs of 
these patients and can counsel them appropriately.  Newborn screening is also an important topic 
covered in most genetic counseling curricula.  Newborn screening is a major public health 
program that has addressed genetic conditions for over 50 years.  The inclusion of HIV is still a 
relatively new practice, but it is a logical extension of a service already in place.  Although HIV 
is not a genetic condition like others screened for on ne wborn screening, it is one where a 
documented intervention has been established to prevent the development of further symptoms 
of clinical infection.  Because the inclusion of HIV on newborn screening panels varies based on 
state, it is  possible that the majority of programs do not  discuss it because it is not relevant 
because they are located in a state that does not include it on its screening panel.   
Programs that did not offer educational material were asked about reasons why they did 
not incorporate these topics into their curricula.   Programs were encouraged to choose the top 
three reasons which accurately described their rationale.  T his question was important to 
understand a program’s reasoning behind not including information and also producing 
additional educational materials.  B y understanding the reasons why programs do not  offer 
education, it is possible to construct the educational materials in a way to take into consideration 
the constraints and barriers to providing this education in the first place. 
The most commonly reported reason why programs do not  address HIV in pregnancy 
within their coursework was a l ack of time and space to incorporate the topic into existing 
curricula.  This response was chosen by 70% programs a major barrier to providing education 
within their curricula.  This response suggests that programs would like to incorporate 
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educational material on HIV in pregnancy if they were able to do s o in a manner that was 
efficient and did not take a large amount of time away from other topics.   
In addition, 50% of programs indicated that one of the reasons they did not include HIV 
in pregnancy within their existing educational content was that the need for the content was not 
warranted because the patient population is not large enough.    T his is an interesting response 
for genetic counselors, as the majority of genetic conditions are rare in the general population.   
No studies have been done to examine the numbers of HIV-positive pregnant women who are 
referred to genetic counseling each year, so it is difficult to clearly identify how large the patient 
population actually is.  It is also possible that in the past genetic counselors were not aware of 
their patient’s HIV status because it was not included on standard prenatal blood tests or because 
patients did not disclose their infection status, so the patient population may have been perceived 
as smaller than it actually was.   It is also possible that counselors do not  have an adequate 
understanding of the extent of the HIV epidemic in women and are not aware that women now 
represent 26% of the HIV disease burden in the United States. A limitation of this study is that 
program directors were not asked about their knowledge regarding issues specific to HIV and 
pregnancy prior to initiating the survey.  It is possible that program directors are not familiar 
with the issues specific to HIV-positive pregnant women and thus would not see how this 
information would be useful to include within curricula for genetic counseling students. If 
programs were to be provided with some background information on the frequency of HIV and 
women and also the numbers of HIV-positive pregnant women choosing to become pregnant 
each year, it is possible that they would re-think that the patient population is too low for HIV 
and pregnancy to be included in education for students.  
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Finally, 40% of programs indicated that counseling about HIV counseling was not the 
role of genetic counselors.  W hen comparing this result to that of the needs assessment, this 
result is surprising.  The relative frequency of this response suggests that a large proportion of 
programs do not think that HIV in pregnancy is an important topic for inclusion within genetic 
counseling program curricula, and thus would not benefit from the development of additional 
educational materials addressing these subjects.  However, the needs assessment found that the 
majority of programs that did not offer any education addressing HIV in pregnancy within their 
curricula felt that they would benefit from the development of additional educational materials.  
The reason for this discrepancy is difficult to determine.  It is possible that program directors do 
not want to take time themselves to develop educational materials addressing HIV in pregnancy, 
but they would gladly accept materials that were developed for them. It is also possible that they 
would want to receive additional educational materials to review them and determine if they 
should be included as a regular part of their program’s curricula.  A final possibility is that 
counselors do not feel comfortable providing education on HIV because of the stigma associated 
with the condition.  HIV is not a condition that is traditionally focused on within genetic 
counseling programs, and program directors may benefit from learning more about the condition 
and its impact on women. 
Overall, the needs assessment found that genetic counseling programs in the United 
States and Canada would benefit from the development of additional educational materials 
addressing HIV in pregnancy.  T his is an important finding that has previously not been 
investigated.  The results indicated a need for additional material among programs that did not 
offer educational material as well as those that did, but the overall need was greater for the 
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former group.  Fisher’s exact test was used to compare the need for additional educational 
materials between the two groups, but a statistically significant difference was not identified.   
 The needs assessment served to understand if programs would benefit from the 
development of additional educational materials.  As mentioned above, the majority of programs 
that did not offer any education addressing HIV in pregnancy, 88.9%, felt they would benefit 
from additional educational materials.  It was hypothesized that differences in need would vary 
among programs of different sizes, specifically that smaller programs would have greater need 
because of more limited resources related to program size.  When the sizes of program were 
compared to the overall need for additional education, the results were not statistically 
significant, although trends were observed suggesting that smaller programs were more likely to 
request additional materials.  Again the inability to identify a significant difference is likely due 
to small sample size, which could not have been corrected in this study because of the limitation 
of the number of programs in the United States and Canada.   
 For programs that currently offered education, the needs assessment found that   64.3% of 
programs felt they would benefit from the development of additional educational materials.   
This result is somewhat surprising, but highlights that although the majority of programs 
currently offer some education regarding HIV in pregnancy, the majority also feel as though 
more information would be beneficial for the instruction of their students.  A gain, it w as 
hypothesized that the size of program may impact the need for additional materials, with smaller 
programs being more likely to believe they would benefit.  Interestingly, the trends seen for 
programs that offered educational material were opposite what was expecting, with larger 
programs being more likely to want additional educational materials as compared to smaller 
programs.  A s expected because of this trend, the results of the J-T test did not identify a 
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statistically significant difference between programs of different sizes. It is not clear why this 
finding was observed, although it is possible that because larger programs were already offering 
education, they were more likely to want additional materials to help strengthen their existing 
content addressing HIV in pregnancy. 
 When reviewing the topics that program directors requested for inclusion in potentially 
developed educational materials, it is interesting to compare them to what is currently available.  
A comparison of broad topics regarding HIV in pregnancy can be seen in Figure 21.    
 
 
Figure 21:  Availability of Education Regarding HIV and Pregnancy in Genetic Counseling Programs vs. 
Need for Additional Educational Material 
 
 As seen, all topics suggested were requested by over than 50% of programs and all but 
one, resource identification, were requested by greater than 70%.  When comparing the currently 
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available topics compared to the requested, it is important to remember that the requested topics 
were submitted by both programs who currently offer education and those that offer none. The 
high response rate for transmission risks during pregnancy and risks during breastfeeding 
indicate that there is a high need among programs who do not  offer education and a need for 
additional information on these topics from programs who already address them.   These results 
also indicate that a clear need exists for additional HIV education beyond transmission risks in 
genetic counseling programs, specifically for materials addressing the 2006 CDC Testing 
Recommendations, Newborn Screening, Clinical Management, and Psychosocial Needs of HIV-
positive pregnant women.   
 For transmission risks, clinical management, psychosocial needs, and resource 
identification, programs were also asked to discuss in more detail what topics they currently 
cover or what topics they would like to see included in developed materials.   
 Figure 22 compares the availability of specific subjects within perinatal transmission 
risks and those that were requested by program directors.   
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Figure 22:  Comparison of Specific Topics Regarding HIV Perinatal transmission Risks Between Programs 
who Currently offer Education and Programs who Requested Additional Materials  
 
The majority of genetic counseling programs who offer education currently discuss 
transmission risks in utero, risks during labor and delivery, and risks associated with early 
invasive diagnostic procedures like amniocentesis and chorionic villus sampling.  These topics 
were also requested by the majority of programs who wanted additional material, again 
suggesting that both programs who offer education and those who don’t think they are important 
for inclusion in genetic counseling curricula.  A  need for development of materials exists for 
recommended methods of delivery, impact on HIV on birth weight, and the risk of HIV crossing 
the placenta, as these were heavily requested but not frequently discussed within currently 
offered discussions addressing HIV and pregnancy. 
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Figure 23 compares the availability of education addressing specific topics for the clinical 
management of HIV-positive pregnant women and the need for additional educational material 
regarding these subjects. 
 
 
Figure 23:  Comparison of Specific Topics Regarding Clinical Management Between Programs who 
Currently offer Education and Programs who Requested Additional Materials 
 
 The majority of programs that offered educational material to their students regarding the 
clinical management of HIV-positive pregnant women addressed teratogenic risks associated 
with antiretroviral medications as well as recommended medications during pregnancy.  These 
are important topics for genetic counselors to know so they are able to identify potential risks 
associated with the use of these medications.  Additionally, the majority of programs currently 
offering education addressed long-term risks to the neonate following exposure to antiretrovirals 
in utero.  These three topics were also highly requested by programs who felt they would benefit 
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from additional educational materials.  T he data also shows that a significant need exists for 
education addressing the recommended medications during pregnancy and delivery, and 
recommended clinical/biological monitoring for HIV-positive pregnant women.  Less than 60% 
of programs felt that the issue of recurrent testing should be addressed in additional educational 
materials, indicating that this topic isn’t of great importance to genetic counselors.  T o help 
support this claim, only about 25% of genetic counseling programs that provide education on 
clinical management include this topic in their discussion. 
Figure 24 compares the availability of education addressing specific psychosocial issues 
HIV-positive women may face and the need for additional educational material regarding these 
subjects. 
 
 
Figure 24:  Comparison of Specific Topics Regarding Psychosocial Issues Between Programs who Currently 
offer Education and Programs who Requested Additional Materials 
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The development of content addressing psychosocial issues was the most requested topic 
for inclusion in educational materials.  All programs surveyed indicated that these topics should 
be included.  Because of the importance of education regarding the psychosocial issues of 
various patient populations within genetic counseling curricula, this result is not surprising.  
When examining the specific psychosocial issues that programs currently address, the most 
commonly discussed are stigma associated with diagnosis, social support issues, and cultural 
competency.  It is important to remember, however, that only a few programs currently 
addressed psychosocial issues within their curricula.  A s was made clear by the needs 
assessment, development of additional materials addressing was very important to program 
directors, and this topic indicated the greatest area of need regarding HIV in pregnancy.   
Programs indicated that a need existed for nearly every psychosocial issue listed, except multiple 
diagnoses.   It is possible that multiple diagnoses was not felt to be as important because genetic 
counseling program directors were familiar with this terminology.  If this study were to be 
repeated, this term would be better explained to mean that women with HIV often have multiple 
diagnoses including other sexually transmitted infections, other chronic infections like 
tuberculosis, or psychiatric illnesses.   
Figure 25 compares the availability of education addressing specific topics for resource 
identification for HIV-positive pregnant women and the need for additional educational material 
regarding these subjects. 
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Figure 25:  Comparison of Specific Topics Regarding Resource Identification Between Programs who 
Currently offer Education and Programs who Requested Additional Materials 
 
Resource identification was the least requested topic chosen for inclusion in developed 
educational materials. Less than 60% of programs asked that it be included in developed 
educational materials.  The need for this topic was similar to the current availability of this topic 
within genetic counseling programs.  This may be due to the fact that programs who do not offer 
education believe they would benefit from its inclusion whereas programs who educate their 
students on resource identification do not think they would benefit from additional educational 
materials.  Additionally, it is possible that because programs do not  offer education on a  wide 
variety of topics regarding HIV in pregnancy, they are not familiar with the variety or 
availability of resources for individuals living with HIV.  Regardless of this, for program 
directors who did indicate that resource identification should be a part of developed materials, a 
definite need was observed specifically for information addressing the availability of HIV case 
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managers/social workers, HIV support services, AIDS Drug Assistance Programs, HIV 
counseling services, and HIV treatment clinics.  Less commonly requested topics were 
information on subsidized housing for individuals with HIV, needle exchange/drug rehabilitation 
programs, legal support, clergy/spiritual support, and child-care support.  Interestingly, the 
majority of these previously mentioned topics were not already included by genetic counseling 
programs who provided education addressing resource identification for HIV-positive pregnant 
women, indicating that programs may not have enough space to incorporate them into existing 
curricula or feel as though individuals with HIV would be better served to learn about these 
resources from other professionals. 
To help address the needs of genetic counseling programs in the United States and 
Canada, the final objective of this project was to develop educational materials designed for 
genetic counseling students addressing issues specific to HIV and pregnancy.  Program directors 
indicated that the three educational materials they would benefit most from were a series of 
online webinars that students could view at any time, clinical case scenarios, and a CD-ROM of 
PowerPoint presentations and other relevant resource materials. The goals of developing the 
educational materials were to address the topics specified by program directors while keeping in 
mind reasons why programs do not  currently offer education addressing HIV and pregnancy.   
Comparing the reasons that programs currently do not provide education addressing HIV and 
pregnancy as well as the specific materials requested, it appears as though counselors chose 
materials that would be relatively simple to incorporate into their existing curricula without the 
addition of much classroom time.  G enetic counseling students could be assigned to view the 
webinars on t heir own time and then discuss some of the issues presented during class.  T he 
clinical case scenarios could be given to students as homework or to do in groups within class.  
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Finally the CD-ROM could be distributed to genetic counseling students to review and explore 
outside of the classroom or even as a resource to keep on hand during clinical rotations in case a 
patient with HIV ever presented.   
Working with the PA/MAAETC, the three most-requested materials were developed.  As 
discussed in the results section, two webinars were designed keeping in mind the needs identified 
by genetic counseling programs.  The first webinar addressing care for HIV-positive pregnant 
women including transmission risks, management, and recommendation was presented live on 
March 2, 2011 and had 106 participants.  5 of these participants identified their primary function 
role as genetic counseling. The second webinar addressing the psychosocial needs and 
approaches to care for HIV-positive women was presented on M arch 16, 2011 a nd had 65 
participants.  7 of these participants identified genetic counseling as their primary function role.   
These webinars will be available on the PA/MAAETC’s website for future viewings, and it is 
hoped that program directors will incorporate them into their existing curricula or recommend 
that students view them outside of the classroom to better understand the needs of women with 
HIV.   
The clinical case examples and CD-ROM discussed in the results section were also 
developed keeping in mind the needs identified by genetic counseling program directors.  The 
clinical case scenarios were designed to weave together common referral reasons that a 
woman/couple may be referred to genetic counseling as well as relevant issues that pertain to 
pregnancy and HIV.  T hese case examples were designed for students to discuss in a group 
setting or in groups to help initiate discussion and develop skills that could be used in a clinical 
setting.   The resource CD was also designed to provide resources and materials which could be 
used to provide education for genetic counseling students.  The resources provided are designed 
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as reference materials as well as quick-access education guides for health care providers.  
Specifically, the Invisible Epidemic series provides a series of patient handouts and health-care 
provider reference sheets addressing issues specific to women with HIV.   
  A future extension of this project will be distributing these educational materials to 
genetic counseling programs in the United States and Canada.  In order to do this, programs will 
be contacted using an email form.  The educational materials will be described, and if program 
directors would like to receive copies of them they will be able to contact the author with the 
proper mailing address to send out the materials.   
Because this is the first study of its kind investigating the current inclusion of information 
addressing HIV in pregnancy and the need for this education in genetic counseling programs, 
there will be a need for follow-up studies.  Following the distribution of materials, it will be 
important to assess program directors’ thoughts on the quality and relevance of the materials.  
Identifying the percentage of programs who requested materials and comparing it to the 
percentage who indicated in this study that they would benefit from development of additional 
materials will be interesting to see if the numbers correlate.  Next, it will be important to assess 
program directors’ opinion of the quality and utility of the developed materials.  Although the 
materials were designed keeping in mind the issues specified from the needs assessment, 
program directors may feel as though the materials could place more emphasis on di fferent 
issues or include additional topics.   Another important issue to be included in follow-up studies 
will be the ease of incorporation of the educational materials into existing curricula.  The 
materials were developed keeping in mind some of the major reasons programs indicated they 
currently did not provide education, especially a lack of time and space to include issues specific 
to HIV in pregnancy.  S tudents within genetic counseling programs should also be asked how 
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they perceive the utility and relevance of the educational materials and if they feel they were 
helpful in their training as genetic counselors.  Assessing the developed educational materials in 
this manner will assist in revisions of content as well as form, and can help aid in the 
development of additional materials which may meet program directors’ needs.  
Long-term evaluation for this project would also be interesting to assess the relevancy of 
the information in genetic counseling practice.  Because this survey was designed and distributed 
only to genetic counseling program directors, the results cannot be applied to practicing prenatal 
genetic counselors due to concerns with external validity.  To examine the relevancy of these 
materials in genetic counseling practices, students who originally received the educational 
materials could be re-surveyed in several years to gage how relevant the information presented is 
to their current practices.  Because genetic counseling graduate programs are two years in length, 
it might be possible to complete this follow-up study 4 years following the delivery of 
educational materials.  If the educational materials developed for genetic counseling programs 
are successful, it mig ht be possible to extend the delivery of these materials to all genetic 
counselors practicing in a prenatal setting who have graduated prior to the development of the 
materials.   
A larger study that would be an important contribution to the development of this topic 
within the literature is to investigate the number of HIV-positive pregnant women are currently 
receiving prenatal genetic counseling in North America.  T hese statistics are currently not 
available because this topics has never been investigated.  This would help clarify the relevance 
of providing education on this topic within genetic counseling programs, categorize the reasons 
why these women are being referred to genetic counseling, and identify additional needs for 
HIV-positive pregnant women that may not have been addressed within this study.  
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Although this study did identify a need for educational materials addressing the needs of 
HIV-positive pregnant women, it is not without its limitations.  One limitation of this study is the 
limited number of genetic counseling programs to survey within the United States and Canada.  
Although the majority of programs who were contacted to participate completed the study, the 
numbers were still not high enough to identify statistical differences between response rates.  
This allows for a qualitative analysis of the findings, but limits the quantitative analysis.  
Because the number of programs is fixed, the low number of responses could not be avoided and 
this should just be an accepted limitation of this study. 
A major limitation of studies done using surveys is non-responder bias.  Responder bias 
is the idea that the individuals who did not respond to the survey differ from those who did.  For 
this study, 32 genetic counseling programs were surveyed, and 26 chose to respond.  Although 
the response rate, 81.26%, is high, it is possible that the 6 programs who chose not to answer 
differ from those who did choose to respond.  Because all data collected from this survey is 
anonymous, it is difficult to compare the responders with the non-responders.  It is possible that 
the programs who chose not to respond did not feel as though the topic studied within the study 
was valuable to their program or due to a lack of interest in the study itself.  If this were the case, 
it would be likely that these individuals would have indicated that their program would not 
benefit from the development of additional educational materials addressing HIV and pregnancy.  
The would mean that the findings of this study overestimate the need for information addressing 
issues specific to HIV-positive pregnant women in genetic counseling programs.    Other reasons 
that programs could not have responded to the survey include improper delivery of the email 
messages or a lack of time. 
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In addition to the non-responder bias, it is also important to consider that two programs 
chose to begin the survey but did not complete it.  These two programs both indicated that they 
currently offered some form of education addressing HIV and pregnancy within their curriculum.  
They did not answer questions regarding the type of materials they used to provide the education 
or what topics they included within their curricula.  These two programs also did not participate 
in the needs assessment.  An important consideration is what caused these two programs to stop 
the survey and also consider if these programs differ from those who completed the survey.  
Comparing the two programs with the little information available, it was observed that one 
program had 0-5 students per year and the other 11-15.  Because these two programs did not 
have the same number of students per academic year, is can be assumed that the size of the 
program did not play a role in the willingness to complete the survey.   It is difficult to speculate 
as to why these programs chose not to finish the survey, but it is possible that after beginning the 
survey, they thought that they rest of the survey was not applicable to them, because of a 
misunderstanding of the questions.  It is possible they thought the rest of the survey 
corresponded only to programs who did not offer educational content addressing HIV and 
pregnancy.  It is also possible that these two programs did not complete the survey because they 
felt that the remaining content was not valuable to their programs.  If this latter possibility were 
the case, it is reasonable to assume that these two programs might have indicated that their 
programs would not benefit from the development of additional educational materials.  T he 
rationale for this could be different from the programs who chose not to respond to the survey 
altogether, however.  Because these two programs already offered content, it is possible they feel 
as though they would not benefit from any additional materials.  This would again inflate the 
findings of the study that a need exists for additional content addressing HIV and pregnancy.    
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Other reasons why these two programs chose not to conclude the survey are a lack of time, or an 
interruption that caused them to stop in the middle.  It is possible that these programs intended to 
return and complete the survey, but were unable to because they forgot, deleted the email, or the 
survey was closed before they could return and complete it.    
Another limitation to this study is that the individuals surveyed were all program 
directors of genetic counseling programs.  Assuming that program directors represent a relatively 
homogenous group of people with similar backgrounds and training, the results of this study 
could be biased and difficult to extend to other groups.  It is also possible that such a large need 
for additional education was found because this population is relatively open to incorporating 
new topics into existing curricula. 
A final limitation of the study is that the issues investigated were specified by the authors 
of the survey.  These topics were hypothesized to be an important part of education for genetic 
counseling students, but it is difficult to separate out if program directors would have specified 
these topics without being presented them in this format.  Also, although program directors were 
given space to indicate additional topics or thoughts, relatively few programs used this option to 
discuss additional topics they felt they would most benefit from or different types of educational 
materials.  W hen examining the topics listed under the ‘other’ category, the majority can be 
incorporated into an already existing topic header.  It is possible that a study which allowed 
program directors to fill in their needs without any prompting by options would have identified 
different results.   
In conclusion, this study was the first of its kind to investigate the current availability of 
education addressing HIV and pregnancy within graduate level genetic counseling programs in 
the United States and Canada.  In addition, this study also examined the programs’ needs for the 
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development of additional education addressing HIV and pregnancy.  This study found that 
although the majority of programs offer some education addressing HIV transmission risks, the 
majority of programs do not address newborn screening, psychosocial issues, clinical 
management, and resource identification. For programs who do not  offer education addressing 
these subjects, the most commonly cited reasons were a l ack of time to include these topics 
within their curricula, the feeling that the patient population was not large enough to warrant 
specific education, and the belief that counseling regarding HIV was not the role of genetic 
counselors.  Despite these reasons for not including education, the needs assessment found that a 
need does exist for additional education within both programs who already offer education and 
those that do not currently address these topics within their curricula.  A substantial need existed 
for education addressing transmission risks during pregnancy, risks associated with 
breastfeeding, clinical management, psychosocial issues, and newborn screening.  A need existed 
for education including information regarding resource identification, but the need was not as 
great for the other topics.  To help meet the needs specified by genetic counseling programs, a 
variety of educational materials were developed for distribution in collaboration with the 
Pennsylvania/MidAtlantic AIDS Education and Training Center.  T he developed materials 
included two webinars which will be able to be accessed anytime online, clinical case examples, 
and a CD-ROM containing PowerPoints and relevant resources for genetic counseling students 
addressing subjects related to HIV in pregnancy. A future direction of this project is to distribute 
these materials to genetic counseling programs in North America  These newly developed 
training materials will help newly trained genetic counselors provide better services to these 
HIV-positive pregnant women and improve the curriculum of genetic counseling programs in the 
United States and Canada.   
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APPENDIX A 
INSTITUTIONAL REVIEW BOARD APPROVAL LETTER 
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APPENDIX B 
PROGRAM DIRECTOR LETTER 
Dear Program Director,  
 
My name is Sara Chadwick and I am a second-year genetic counseling student at the University 
of Pittsburgh’s Graduate School of Public Health.  I am also employed by the 
Pennsylvania/MidAtlantic AIDS Education and Training Center (PA/MAAETC), a non-profit 
organization funded by the U.S. Public Health Service’s Health Resources Service 
Administration (HRSA).  The (PA/MAAETC) recognizes the complicated issues of providing 
quality HIV/AIDS care and focuses on the entire health care team including physicians, nurses, 
dentists, advanced practice nurses, physician assistants, pharmacists and other health care 
professionals. The AETC custom designs programs, taking into account the providers' rural or 
urban settings, experience, and volume of HIV patients. 
 
For my master’s thesis, I am conducting a survey of program directors of genetic counseling 
programs in the United States and Canada.  T his survey asks questions regarding existing 
curricula content available for genetic counseling students on H IV/AIDS in pregnancy.  
Specifically, this survey considers issues regarding HIV-positive pregnant women.   
 
A study conducted by Emory University indicates that the average lifespan of a person following 
an HIV diagnosis has increased from 7 years in 1993 t o 24 years in 2006.  D ue to treatment 
improvements, HIV is now largely becoming a chronic disease requiring lifelong management.  
Today, many women with HIV may consider having children due to increased life expectancy 
and increased quality of life.  The CDC estimates that approximately 6000 to 7000 women living 
with HIV will choose to become pregnant each year.   P erinatal transmission of HIV is the 
leading cause of HIV in children in the United States.  However, treatment of HIV-positive 
pregnant women with antiretrovirals during pregnancy can drastically reduce the risk of perinatal 
infection, and this has led the CDC to recommend HIV testing in all pregnant women.  This has 
also prompted some states to include HIV testing in their newborn screening programs.  Because 
of the increasing numbers of HIV-positive women who are living longer and thus may be 
making decisions to have families and the decision of states to include HIV testing of newborns, 
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the needs of HIV-positive women will likely become relevant in the field of genetic counseling.   
HIV is not a genetic condition that would be the object of focus during a counseling session; 
however it is clear that women with HIV have unique psychosocial needs and medical issues that 
should be taken into consideration during a counseling session.  H IV is part of a woman’s 
medical history, and this diagnosis can have implications on treatments, medication interactions, 
and recommendations for certain procedures during pregnancy.  Women with HIV are not just 
women with HIV, they are women who are being referred for counseling due to advanced 
maternal age, genetic risk, medication exposure, and any other number of reasons that a women 
without HIV would seek genetic counseling. 
 
I would greatly appreciate it if you would take a few minutes to complete the survey I have 
designed and uploaded onto survey monkey.com.  T he link for this survey is Existing 
Educational Content Regarding HIV-positive Pregnant Women in Genetic Counseling Programs.   
All answers collected from this survey will be completely anonymous, and will help serve to 
investigate the current educational HIV content utilized by genetic counseling programs in the 
United States and Canada and help me develop educational materials to facilitate the 
incorporation of the special needs of an HIV-positive woman receiving prenatal counseling into 
existing curricula.  
 
Thank you so much for your participation in my survey and helping me complete my master’s 
thesis.  I greatly appreciate your time and cooperation. 
 
 
 
Sara Chadwick, MPH, CPH 
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APPENDIX C 
SURVEY FOR GENETIC COUNSELING PROGRAMS 
Introduction:  The purpose of this survey is to ascertain curricular content regarding the 
counseling of HIV-positive women in a prenatal setting.  Please answer these questions 
regarding your program’s availability of education for its students on the topics described as well 
as what materials might be valuable to you as a program director. The survey should take 
approximately 15 minutes.  There are no foreseeable risks associated with this project, nor are 
there any direct benefits to you.  You will not receive any payment for participation.   All 
answers collected from this survey will be completely anonymous, and your responses will not 
be identifiable in any way.  All responses are confidential, and results will be kept under lock 
and key.  Your participation is voluntary, and you may withdraw from this project at any time.   
If you have any questions or wish to contact me, my e-mail address is slc84@pitt.edu. 
1.  How many students are enrolled in each year your program?      
_________ 0-5 
_________ 6-10 
_________ 11-15 
 
2. Does your Genetic Counseling program provide educational content about HIV/AIDS in 
pregnancy in any courses? 
Yes _______              No_________ 
 
If yes, do you provide education in the form of: 
_______ One lecture on HIV in pregnancy 
_______ More than one lecture on HIV in pregnancy 
 118 
_______ Content on HIV and pregnancy within another lecture 
_______ Required reading on HIV in pregnancy 
_______ Optional reading on HIV in pregnancy 
_______ Required web-based tutorial on HIV in pregnancy 
_______ Optional web-based tutorial on HIV in pregnancy 
_______ Required documentary or film addressing HIV in pregnancy 
_______ Optional documentary or film addressing HIV in pregnancy 
_______ Other.  Please describe briefly in the space below. 
 
If you answered yes, proceed to question 3. 
If you answered no, proceed to question 10. 
 
3.  Do you provide educational content in the curriculum on HIV in women and the risk of 
HIV perinatal transmission? 
Yes________         No_________ 
 
If yes, do you address: (check all that apply) 
_______ HIV crossing the placenta 
_______ Transmission risk in utero  
_______ Transmission risks during delivery 
_______ Impact of HIV in pregnancy and lower birth weight babies 
_______ Current recommended methods of delivery 
_______ Risks of transmission during amniocentesis/chorionic villus sampling 
_______ Other.  Please describe briefly in the space below. 
 
 
4. Do you provide educational content in the curriculum on the risk of HIV perinatal 
transmission to babies born to HIV-positive mothers by breast feeding? 
Yes________         No_________ 
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5. Do you provide curriculum content on the 2006 Center for Disease Control and 
Prevention’s Recommendations for HIV screening in pregnant women? 
Yes________         No_________ 
 
6. Do you provide curriculum content on the current states where HIV screening is included 
in newborn screening programs? 
Yes________         No_________ 
 
7. Do you provide curriculum content on the current clinical management of HIV infection 
in pregnant women?  
Yes________         No_________ 
 
If yes, do you address:  (check all that apply) 
_______ Current recommended HIV antiretroviral medications 
_______ Teratogenic risks of HIV antiretroviral medications 
_______ Long-term risks to the neonate from HIV antiretroviral exposure in utero 
_______ Recommendations for HIV antiretroviral medications during labor and delivery 
_______ Clinical biological monitoring (CD4+ count, viral load) during pregnancy 
_______ Need for recurring HIV testing upon entry to Ob/Gyn care and at labor and 
   delivery 
_______ Interactions between HIV medications, other prescribed medications, over the  
    counter drugs, and street drugs 
_______ Other.  Please describe briefly in the space below.  
 
8.  Do you provide curriculum content on psychosocial needs of pregnant HIV-positive 
women who receive counseling? 
Yes________         No_________ 
 
If yes, do you address the following: (check all that apply) 
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_______ Psychiatric sequelae of HIV 
_______ Cultural competence 
_______ Social support issues 
_______ Substance use/abuse 
_______ Sexual/domestic violence 
_______ Stigma associated with diagnosis 
_______ Depression/suicide risk 
_______ Anxiety 
_______ Multiple diagnoses 
_______ Other.  Please describe briefly in the space below. 
 
9. Do you provide curriculum content on available resources in your area?  
Yes ________             No_________ 
 
If yes, do you address the following: (check all that apply) 
_______ AIDS drug assistance programs (payment for medications)  
_______ Available HIV case managers/social workers  
_______ Child care services 
_______ Clergy, spiritual support. 
_______ HIV counseling services 
_______ HIV support groups 
_______ HIV treatment clinics in the area  
_______ Legal services  
_______ Needle exchange programs/ substance abuse rehabilitation programs 
_______ Subsidized housing for HIV-positive persons 
_______ Other.  Please describe briefly in the space below. 
 
Please skip to question 12.   
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10. If you do not provide any education to your students on HIV/AIDS, why not? (check 
TOP THREE CHOICES) 
_______ Counseling about HIV is not the role of genetic counselors  
_______ Conflict with program goals 
_______ Insufficient faculty knowledge regarding HIV/AIDS during pregnancy 
_______ Lack of availability of educational materials 
_______ Lack of course time/space to incorporate topic 
_______ Lack of knowledgeable faculty 
_______ Need for specific curriculum content is not warranted (patient population is not  
    large enough) 
_______ Students have not requested the topic to be covered 
_______ Training on HIV-positive pregnant women not needed  
_______ Other (please identify below) 
11. If you do not provide education to your students on HIV/AIDS, do you think your 
program would benefit from the development of educational materials designed to 
address issues regarding HIV/AIDS and pregnancy? 
Yes ________             No_________ 
 
If you answered yes, please proceed to question 13. 
If you answered no, you are done with this survey, thank you for your input! 
 
12. If you do provide education to your students on HIV/AIDS, do you think your program 
would benefit from the development of additional educational materials that are designed 
to address issues regarding HIV/AIDS and pregnancy? 
Yes ________             No_________ 
 
If you answered yes, please proceed to question 13. 
If you answered no, you are done with this survey, thank you for your input! 
 
 122 
13. Which of the following topics do you think the educational materials should address? 
(check all major categories that apply, and then check specific topics within that 
category) 
_______ Content on the risk of HIV in women and the risk of HIV perinatal transmission 
 _______ HIV crossing the placenta 
 _______ Transmission risks in utero 
_______ Transmission risks during delivery 
_______ Impact of HIV in pregnancy and lower birth weight babies 
_______ Current recommended methods of delivery 
_______ Risks of transmission during amniocentesis/chorionic villus sampling 
_______ Content on the risk of HIV perinatal transmission to babies born to HIV- 
    positive  mothers by breast feeding 
_______ Content on the 2006 Center for Disease Control and Prevention’s  
    recommendations for HIV screening in pregnant women 
_______ Content on the current states where HIV screening is included in newborn  
    screening programs 
_______ Content on the current clinical management of HIV infection in pregnant 
    women 
_______ Current recommended HIV antiretroviral medications  
_______ Teratogenic risks of HIV antiretroviral medications 
_______ Long-term risks to the neonate from HIV antiretroviral exposure in utero 
_______ Recommendations for HIV antiretroviral medications during labor and  
    delivery 
_______ Clinical biological monitoring (CD4+ count, viral load) during  
    pregnancy 
_______ Need for recurring HIV testing upon entry to Ob/Gyn care and labor and  
    delivery 
_______ Interactions between HIV medications, other prescribed medications,  
    over the counter drugs, and street drugs.  
_______ Content on psychosocial needs of pregnant HIV-positive women 
 _______ Psychiatric sequelae of HIV 
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_______ Cultural competency 
_______ Social support issues 
_______ Substance use/abuse 
_______ Sexual/domestic violence 
_______ Stigma associated with diagnosis 
_______ Depression/suicide risk 
_______ Anxiety 
_______ Multiple diagnoses 
_______ Content on available resources in your area 
 _______ AIDS drug assistance programs (payment for medications)  
_______ Available HIV case managers/social workers  
_______ Child care services 
_______ Clergy, spiritual support. 
_______ HIV counseling services 
_______ HIV support groups 
_______ HIV treatment clinics in the area  
_______ Legal services  
_______ Needle exchange programs/ substance abuse rehabilitation programs 
_______ Subsidized housing for HIV-positive persons 
_______ Other/Additional Topics (please describe below) 
 
 
14. Which of the following educational materials do you feel that you might use as a program 
director in educating your students about HIV in pregnancy? (check TOP THREE 
choices) 
_______  CD-ROM of PowerPoint lectures addressing HIV basics, perinatal transmission  
     risks, current CDC recommendations for HIV screening in pregnancy, and the  
     implications for genetic counselors of counseling an HIV-positive pregnant  
     woman 
_______ Pocket-guide on HIV in pregnant women for genetic counselors (a pocket guide  
    is a condensed summary of important material on a topic) 
_______ Clinical case examples which can illustrate key points of counseling HIV  
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    positive women in a genetic counseling practice 
_______ Series of online webcasts that could be viewed at any time by students 
_______ Packets of relevant peer-reviewed research articles which can be used to  
    facilitate discussion 
_______ Series of audio lectures that address HIV and pregnancy 
_______ List of current documentaries, books, popular movies, etc. that illustrate the  
    needs of an HIV-infected patient 
_______ Quizzes on relevant topics in HIV education for genetic counselors 
_______ Role playing scenarios that could be used in class by students to practice skills  
    learned 
_______ List of websites that would be valuable resources for faculty and students   
_______ Other.  Please describe briefly below. 
 
 
Thank you for your input! 
 
 
This survey was created by the following:   
Sara L. Chadwick, MPH, CPH  
Linda R. Frank, PhD, MSN, ACRN, FAAN 
Elizabeth Gettig, MS, CGC 
Robin E. Grubs, PhD, CGC 
 
Last updated:  June 2010 
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